BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet 2012;380:1590-605. [DOI: 10.1016/s0140-6736(12)60026-9] [Cited by in Crossref: 1109] [Cited by in F6Publishing: 537] [Article Influence: 123.2] [Reference Citation Analysis]
Number Citing Articles
1 Feng Y, Liao Y, Huang W, Lai X, Luo J, Du C, Lin J, Zhang Z, Qiu D, Liu Q, Shen H, Xiang AP, Zhang Q. Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis. Cell Death Dis. 2018;9:691. [PMID: 29880866 DOI: 10.1038/s41419-018-0734-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
2 Kiernan MG, Coffey JC, Sahebally SM, Tibbitts P, Lyons EM, O'leary E, Owolabi F, Dunne CP. Systemic Molecular Mediators of Inflammation Differentiate Between Crohn's Disease and Ulcerative Colitis, Implicating Threshold Levels of IL-10 and Relative Ratios of Pro-inflammatory Cytokines in Therapy. J Crohns Colitis 2020;14:118-29. [PMID: 31241755 DOI: 10.1093/ecco-jcc/jjz117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
3 Chinnadurai R, Waller EK, Galipeau J, Nooka AK. From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseases. Biomed Res Int 2013;2013:929842. [PMID: 24350294 DOI: 10.1155/2013/929842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q. Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn’s disease in China. World J Gastroenterol 2020; 26(41): 6455-6474 [PMID: 33244205 DOI: 10.3748/wjg.v26.i41.6455] [Reference Citation Analysis]
5 Ruder B, Becker C. At the Forefront of the Mucosal Barrier: The Role of Macrophages in the Intestine. Cells 2020;9:E2162. [PMID: 32987848 DOI: 10.3390/cells9102162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
6 Stevens BW, Borren NZ, Velonias G, Conway G, Cleland T, Andrews E, Khalili H, Garber JG, Xavier RJ, Yajnik V, Ananthakrishnan AN. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Dig Dis Sci 2017;62:197-206. [PMID: 27796768 DOI: 10.1007/s10620-016-4356-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
7 Qiu XM, Jiang L. [New diagnostic classification of cheilitis and its clinical diagnostic pathway]. Hua Xi Kou Qiang Yi Xue Za Zhi 2021;39:238-44. [PMID: 33834683 DOI: 10.7518/hxkq.2021.02.019] [Reference Citation Analysis]
8 Small CL, Xing L, McPhee JB, Law HT, Coombes BK. Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period. PLoS Pathog. 2016;12:e1005907. [PMID: 27711220 DOI: 10.1371/journal.ppat.1005907] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
9 Bernardi L, Santos CHMD, Pinheiro VAZ, Oliveira RJ, Antoniolli-Silva ACMB. TRANSPLANTATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN REFRACTORY CROHN'S DISEASE: SYSTEMATIC REVIEW. Arq Bras Cir Dig 2019;32:e1465. [PMID: 31859918 DOI: 10.1590/0102-672020190001e1465] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
10 Schindlbeck KA, Becker J, Berger F, Mehl A, Rewitzer C, Geffe S, Koch PM, Preiß JC, Siegmund B, Maul J, Marzinzik F. Impact of restless legs syndrome in patients with inflammatory bowel disease on sleep, fatigue, and quality of life. Int J Colorectal Dis 2017;32:125-30. [PMID: 27757540 DOI: 10.1007/s00384-016-2681-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
11 McNees AL, Markesich D, Zayyani NR, Graham DY. Mycobacterium paratuberculosis as a cause of Crohn's disease. Expert Rev Gastroenterol Hepatol 2015;9:1523-34. [PMID: 26474349 DOI: 10.1586/17474124.2015.1093931] [Cited by in Crossref: 64] [Cited by in F6Publishing: 58] [Article Influence: 10.7] [Reference Citation Analysis]
12 Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet 2017;56:1513-23. [PMID: 28353055 DOI: 10.1007/s40262-017-0535-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
13 Li H, Lyu W. Intestinal NK/T cell lymphoma: A case report. World J Gastroenterol 2020; 26(27): 3989-3997 [PMID: 32774072 DOI: 10.3748/wjg.v26.i27.3989] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wurbel MA, Le Bras S, Ibourk M, Pardo M, McIntire MG, Coco D, Geha RS, Fiebiger E, Snapper SB. CCL25/CCR9 interactions are not essential for colitis development but are required for innate immune cell protection from chronic experimental murine colitis. Inflamm Bowel Dis 2014;20:1165-76. [PMID: 24874458 DOI: 10.1097/MIB.0000000000000059] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
15 Besednova NN, Zaporozhets TS, Kuznetsova TA, Makarenkova ID, Kryzhanovsky SP, Fedyanina LN, Ermakova SP. Extracts and Marine Algae Polysaccharides in Therapy and Prevention of Inflammatory Diseases of the Intestine. Mar Drugs 2020;18:E289. [PMID: 32486405 DOI: 10.3390/md18060289] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
16 Alawi F. An update on granulomatous diseases of the oral tissues. Dent Clin North Am 2013;57:657-71. [PMID: 24034071 DOI: 10.1016/j.cden.2013.07.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
17 Celentano V, O'Leary DP, Caiazzo A, Flashman KG, Sagias F, Conti J, Senapati A, Khan J. Longer small bowel segments are resected in emergency surgery for ileocaecal Crohn's disease with a higher ileostomy and complication rate. Tech Coloproctol 2019;23:1085-91. [PMID: 31664551 DOI: 10.1007/s10151-019-02104-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
18 Cai C, Zhu S, Tong J, Wang T, Feng Q, Qiao Y, Shen J. Relating the transcriptome and microbiome by paired terminal ileal Crohn disease. iScience 2021;24:102516. [PMID: 34113837 DOI: 10.1016/j.isci.2021.102516] [Reference Citation Analysis]
19 Tremblay É, Thibault MP, Ferretti E, Babakissa C, Bertelle V, Bettolli M, Burghardt KM, Colombani JF, Grynspan D, Levy E, Lu P, Mayer S, Ménard D, Mouterde O, Renes IB, Seidman EG, Beaulieu JF. Gene expression profiling in necrotizing enterocolitis reveals pathways common to those reported in Crohn's disease. BMC Med Genomics 2016;9:6. [PMID: 26801768 DOI: 10.1186/s12920-016-0166-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
20 Schoultz M, Atherton I, Watson A. Mindfulness-based cognitive therapy for inflammatory bowel disease patients: findings from an exploratory pilot randomised controlled trial. Trials. 2015;16:379. [PMID: 26303912 DOI: 10.1186/s13063-015-0909-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
21 Makharia GK. Quality of care in Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(4): 462-466 [PMID: 25400990 DOI: 10.4291/wjgp.v5.i4.462] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis 2015;21:323-30. [PMID: 25545378 DOI: 10.1097/MIB.0000000000000264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
23 Ye L, Zhang YP, Yu N, Jia YX, Wan SJ, Wang FY. Serum platelet factor 4 is a reliable activity parameter in adult patients with inflammatory bowel disease: A pilot study. Medicine (Baltimore) 2017;96:e6323. [PMID: 28296751 DOI: 10.1097/MD.0000000000006323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
24 Fortinsky KJ, Kevans D, Qiang J, Xu W, Bellolio F, Steinhart H, Milgrom R, Greenberg G, Cohen Z, Macrae H, Stempak J, McLeod R, Silverberg MS. Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease. Dig Dis Sci. 2017;62:188-196. [PMID: 27778204 DOI: 10.1007/s10620-016-4351-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Balart MT, Russell L, Narula N, Bajaj G, Chauhan U, Khan KJ, Marwaha AN, Ching E, Biro J, Halder S, Tse F, Marshall JK, Collins SM, Moayyedi P, Bercik P, Verdu EF, Leontiadis GI, Armstrong D, Pinto-Sanchez MI. Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. J Can Assoc Gastroenterol 2021;4:214-21. [PMID: 34617003 DOI: 10.1093/jcag/gwaa037] [Reference Citation Analysis]
26 Marlow GJ, van Gent D, Ferguson LR. Why interleukin-10 supplementation does not work in Crohn’s disease patients. World J Gastroenterol 2013; 19(25): 3931-3941 [PMID: 23840137 DOI: 10.3748/wjg.v19.i25.3931] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 78] [Article Influence: 11.5] [Reference Citation Analysis]
27 Fuchs F, Schillinger D, Atreya R, Hirschmann S, Fischer S, Neufert C, Atreya I, Neurath MF, Zundler S. Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. Front Immunol 2017;8:764. [PMID: 28717358 DOI: 10.3389/fimmu.2017.00764] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
28 Bertani L, Baglietto L, Antonioli L, Fornai M, Tapete G, Albano E, Ceccarelli L, Mumolo MG, Pellegrini C, Lucenteforte E, de Bortoli N, Bellini M, Marchi S, Blandizzi C, Costa F. Assessment of serum cytokines predicts clinical and endoscopic outcomes to vedolizumab in ulcerative colitis patients. Br J Clin Pharmacol 2020;86:1296-305. [PMID: 32027388 DOI: 10.1111/bcp.14235] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
29 Pagnini C, Cominelli F. Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention. Int J Mol Sci 2021;22:10273. [PMID: 34638616 DOI: 10.3390/ijms221910273] [Reference Citation Analysis]
30 Moćko P, Kawalec P, Smela-Lipińska B, Pilc A. Effectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysis. Arch Med Sci 2016;12:1088-96. [PMID: 27695501 DOI: 10.5114/aoms.2016.61915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
31 Miyazu T, Ishida N, Takano R, Tamura S, Yamade M, Hamaya Y, Tani S, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission. Medicine (Baltimore) 2021;100:e26550. [PMID: 34398010 DOI: 10.1097/MD.0000000000026550] [Reference Citation Analysis]
32 Zibandeh N, Genc D, Duran Y, Banzragch M, Sokwala S, Goker K, Atug O, Akkoç T. Human dental follicle mesenchymal stem cells alleviate T cell response in inflamed tissue of Crohn's patients. Turk J Gastroenterol 2020;31:400-9. [PMID: 32519960 DOI: 10.5152/tjg.2020.19358] [Reference Citation Analysis]
33 Deepak P, Fletcher JG, Fidler JL, Bruining DH. Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis. 2016;22:2280-2288. [PMID: 27508513 DOI: 10.1097/mib.0000000000000845] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
34 Poyato-Borrego M, Segura-Egea JJ, Martín-González J, Jiménez-Sánchez MC, Cabanillas-Balsera D, Areal-Quecuty V, Segura-Sampedro JJ. Prevalence of endodontic infection in patients with Crohn´s disease and ulcerative colitis. Med Oral Patol Oral Cir Bucal 2021;26:e208-15. [PMID: 32851982 DOI: 10.4317/medoral.24135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lin C, Zhang J. Inflammasomes in Inflammation-Induced Cancer. Front Immunol 2017;8:271. [PMID: 28360909 DOI: 10.3389/fimmu.2017.00271] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
36 Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut 2018;67:1824-35. [PMID: 28982740 DOI: 10.1136/gutjnl-2016-313457] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 12.5] [Reference Citation Analysis]
37 Higueras MÁ, Jiménez-García L, Herranz S, Hortelano S, Luque A. Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response. J Vis Exp 2017. [PMID: 28994756 DOI: 10.3791/55824] [Reference Citation Analysis]
38 Shim HH, Ma C, Kotze PG, Seow CH, Al-Farhan H, Al-Darmaki AK, Pang JXQ, Fedorak RN, Devlin SM, Dieleman LA, Kaplan GG, Novak KL, Kroeker KI, Halloran BP, Panaccione R. Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. J Can Assoc Gastroenterol 2018;1:115-23. [PMID: 31294352 DOI: 10.1093/jcag/gwy013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
39 Zou Y, Lin J, Li W, Wu Z, He Z, Huang G, Wang J, Ye C, Cheng X, Ding C, Zheng X, Chi H. Huangqin-tang ameliorates dextran sodium sulphate-induced colitis by regulating intestinal epithelial cell homeostasis, inflammation and immune response. Sci Rep. 2016;6:39299. [PMID: 27982094 DOI: 10.1038/srep39299] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
40 Lindström U, Olofsson T, Wedrén S, Qirjazo I, Askling J. Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis: a population-based nationwide study. RMD Open 2018;4:e000762. [PMID: 30402269 DOI: 10.1136/rmdopen-2018-000762] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
41 Castro-Mejía J, Jakesevic M, Krych Ł, Nielsen DS, Hansen LH, Sondergaard BC, Kvist PH, Hansen AK, Holm TL. Treatment with a Monoclonal Anti-IL-12p40 Antibody Induces Substantial Gut Microbiota Changes in an Experimental Colitis Model. Gastroenterol Res Pract 2016;2016:4953120. [PMID: 26880890 DOI: 10.1155/2016/4953120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
42 Dobre M, Milanesi E, Mănuc TE, Arsene DE, Ţieranu CG, Maj C, Becheanu G, Mănuc M. Differential Intestinal Mucosa Transcriptomic Biomarkers for Crohn's Disease and Ulcerative Colitis. J Immunol Res 2018;2018:9208274. [PMID: 30417021 DOI: 10.1155/2018/9208274] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
43 Liverani E, Scaioli E, Cardamone C, Monte PD, Belluzzi A. Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn’s disease, cause or epiphenomenon? World J Gastroenterol 2014; 20(36): 13060-13070 [PMID: 25278700 DOI: 10.3748/wjg.v20.i36.13060] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
44 Garg R, Mohan BP, Ponnada S, Regueiro M, Lightner AL, Click B. Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn's disease: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:691-8. [PMID: 34475740 DOI: 10.20524/aog.2021.0634] [Reference Citation Analysis]
45 Xiang XW, Wang R, Yao LW, Zhou YF, Sun PL, Zheng B, Chen YF. Anti-Inflammatory Effects of Mytilus coruscus Polysaccharide on RAW264.7 Cells and DSS-Induced Colitis in Mice. Mar Drugs 2021;19:468. [PMID: 34436307 DOI: 10.3390/md19080468] [Reference Citation Analysis]
46 Yajnik V, Khan N, Dubinsky M, Axler J, James A, Abhyankar B, Lasch K. Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. Adv Ther 2017;34:542-59. [PMID: 28070861 DOI: 10.1007/s12325-016-0467-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
47 Krug SM, Bojarski C, Fromm A, Lee IM, Dames P, Richter JF, Turner JR, Fromm M, Schulzke JD. Tricellulin is regulated via interleukin-13-receptor α2, affects macromolecule uptake, and is decreased in ulcerative colitis. Mucosal Immunol 2018;11:345-56. [PMID: 28612843 DOI: 10.1038/mi.2017.52] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
48 Milia AF, Ruffo M, Manetti M, Rosa I, Conte D, Fazi M, Messerini L, Ibba-Manneschi L. Telocytes in Crohn's disease. J Cell Mol Med 2013;17:1525-36. [PMID: 24251911 DOI: 10.1111/jcmm.12177] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 8.5] [Reference Citation Analysis]
49 Bamias G, Pizarro TT, Cominelli F. Pathway-based approaches to the treatment of inflammatory bowel disease. Transl Res 2016;167:104-15. [PMID: 26408803 DOI: 10.1016/j.trsl.2015.09.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
50 Vardi I, Chermesh I, Werner L, Barel O, Freund T, McCourt C, Fisher Y, Pinsker M, Javasky E, Weiss B, Rechavi G, Hagin D, Snapper SB, Somech R, Konnikova L, Shouval DS. Monogenic Inflammatory Bowel Disease: It's Never Too Late to Make a Diagnosis. Front Immunol 2020;11:1775. [PMID: 33013830 DOI: 10.3389/fimmu.2020.01775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Yang FC, Chiu PY, Chen Y, Mak TW, Chen NJ. TREM-1-dependent M1 macrophage polarization restores intestinal epithelium damaged by DSS-induced colitis by activating IL-22-producing innate lymphoid cells. J Biomed Sci 2019;26:46. [PMID: 31189465 DOI: 10.1186/s12929-019-0539-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
52 Moore C, Jakate S, Keshavarzian A. An Esophagogastroduodenal Crohn's-Like Disease in a Long-Standing Pan-Ulcerative Colitis Patient. Case Rep Gastrointest Med 2014;2014:464139. [PMID: 25295198 DOI: 10.1155/2014/464139] [Reference Citation Analysis]
53 Casalino G, Querques G, Corvi F, Borrelli E, Triolo G, Ramirez GA, Bandello F. Choroidal neovascularization in a patient with Crohn's disease. Case Rep Ophthalmol 2014;5:249-54. [PMID: 25232338 DOI: 10.1159/000365881] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
54 Yu HC, Chen TP, Chang YC. Inflammatory bowel disease as a risk factor for periodontitis under Taiwanese National Health Insurance Research database. J Dent Sci 2018;13:242-7. [PMID: 30895127 DOI: 10.1016/j.jds.2018.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
55 Ciccocioppo R, Racca F, Scudeller L, Piralla A, Formagnana P, Pozzi L, Betti E, Vanoli A, Riboni R, Kruzliak P, Baldanti F, Corazza GR. Differential cellular localization of Epstein-Barr virus and human cytomegalovirus in the colonic mucosa of patients with active or quiescent inflammatory bowel disease. Immunol Res 2016;64:191-203. [PMID: 26659090 DOI: 10.1007/s12026-015-8737-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
56 Krabs RU, Enk R, Teich N, Koelsch S. Autonomic effects of music in health and Crohn's disease: the impact of isochronicity, emotional valence, and tempo. PLoS One 2015;10:e0126224. [PMID: 25955253 DOI: 10.1371/journal.pone.0126224] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
57 Duran NE, Hommes DW. Stem cell-based therapies in inflammatory bowel disease: promises and pitfalls. Therap Adv Gastroenterol 2016;9:533-47. [PMID: 27366222 DOI: 10.1177/1756283X16642190] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 4.4] [Reference Citation Analysis]
58 Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn’s strictures open with anti-mycobacterial antibiotic therapy: A retrospective review. World J Gastrointest Endosc 2020; 12(12): 542-554 [PMID: 33362907 DOI: 10.4253/wjge.v12.i12.542] [Cited by in CrossRef: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014;7:5. [PMID: 24678903 DOI: 10.1186/1755-1536-7-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 7.0] [Reference Citation Analysis]
60 Leroux LP, Nasr M, Valanparambil R, Tam M, Rosa BA, Siciliani E, Hill DE, Zarlenga DS, Jaramillo M, Weinstock JV, Geary TG, Stevenson MM, Urban JF Jr, Mitreva M, Jardim A. Analysis of the Trichuris suis excretory/secretory proteins as a function of life cycle stage and their immunomodulatory properties. Sci Rep 2018;8:15921. [PMID: 30374177 DOI: 10.1038/s41598-018-34174-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
61 Henson MA, Phalak P. Microbiota dysbiosis in inflammatory bowel diseases: in silico investigation of the oxygen hypothesis. BMC Syst Biol 2017;11:145. [PMID: 29282051 DOI: 10.1186/s12918-017-0522-1] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
62 Choo J, Lee Y, Yan XJ, Noh TH, Kim SJ, Son S, Pothoulakis C, Moon HR, Jung JH, Im E. A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis. J Biol Chem 2015;290:25609-19. [PMID: 26342083 DOI: 10.1074/jbc.M115.673046] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
63 Borecki K, Zawada I, Pawinska-Matecka A, Salkic NN, Karakiewicz B, Adler G. ABCB1 3435C>T and 2677G>T/A polymorphisms in Polish and Bosnian patients with Crohn's disease - A preliminary report. Bosn J Basic Med Sci 2017;17:323-7. [PMID: 28759738 DOI: 10.17305/bjbms.2017.2172] [Reference Citation Analysis]
64 Bendix M, Greisen S, Dige A, Hvas CL, Bak N, Jørgensen SP, Dahlerup JF, Deleuran B, Agnholt J. Vitamin D increases programmed death receptor-1 expression in Crohn's disease. Oncotarget 2017;8:24177-86. [PMID: 28412753 DOI: 10.18632/oncotarget.15489] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
65 Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. 2014;7:6-19. [PMID: 24084775 DOI: 10.1038/mi.2013.73] [Cited by in Crossref: 192] [Cited by in F6Publishing: 188] [Article Influence: 24.0] [Reference Citation Analysis]
66 Schäffler H, Demircioglu DD, Kühner D, Menz S, Bender A, Autenrieth IB, Bodammer P, Lamprecht G, Götz F, Frick JS. NOD2 stimulation by Staphylococcus aureus-derived peptidoglycan is boosted by Toll-like receptor 2 costimulation with lipoproteins in dendritic cells. Infect Immun 2014;82:4681-8. [PMID: 25156723 DOI: 10.1128/IAI.02043-14] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
67 de Barros KSC, Flores C, Harlacher L, Francesconi CFM. Evolution of Clinical Behavior in Crohn's Disease: Factors Associated with Complicated Disease and Surgery. Dig Dis Sci 2017;62:2481-8. [PMID: 28748409 DOI: 10.1007/s10620-017-4685-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
68 Sahrmann P, Gilli F, Wiedemeier DB, Attin T, Schmidlin PR, Karygianni L. The Microbiome of Peri-Implantitis: A Systematic Review and Meta-Analysis. Microorganisms 2020;8:E661. [PMID: 32369987 DOI: 10.3390/microorganisms8050661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
69 Ciccocioppo R, Dos Santos CC, Baumgart DC, Cangemi GC, Cardinale V, Ciacci C, De Coppi P, Haldar D, Klersy C, Nostro MC, Ott M, Piemonti L, Tomei AA, Uygun B, Vetrano S, Orlando G. Proceedings of the signature series event of the international society for cellular therapy: "Advancements in cellular therapies and regenerative medicine in digestive diseases," London, United Kingdom, May 3, 2017. Cytotherapy 2018;20:461-76. [PMID: 29398624 DOI: 10.1016/j.jcyt.2017.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
70 Jiang P, Mizushima N. Autophagy and human diseases. Cell Res. 2014;24:69-79. [PMID: 24323045 DOI: 10.1038/cr.2013.161] [Cited by in Crossref: 506] [Cited by in F6Publishing: 489] [Article Influence: 63.3] [Reference Citation Analysis]
71 Leber A, Hontecillas R, Zoccoli-Rodriguez V, Bienert C, Chauhan J, Bassaganya-Riera J. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol 2019;203:3407-15. [PMID: 31694910 DOI: 10.4049/jimmunol.1900364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
72 Truyens M, De Ruyck E, Gonzales GB, Bos S, Laukens D, De Vos M. Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals. J Clin Med 2021;10:4107. [PMID: 34575218 DOI: 10.3390/jcm10184107] [Reference Citation Analysis]
73 Rahme E, Nedjar H, Afif W. Cost of Refractory Crohn's Disease Before and After Ustekinumab Utilization. J Can Assoc Gastroenterol 2020;3:257-65. [PMID: 33241178 DOI: 10.1093/jcag/gwz025] [Reference Citation Analysis]
74 Ren Z, Jiang J, Lu H, Chen X, He Y, Zhang H, Xie H, Wang W, Zheng S, Zhou L. Intestinal microbial variation may predict early acute rejection after liver transplantation in rats. Transplantation. 2014;98:844-852. [PMID: 25321166 DOI: 10.1097/tp.0000000000000334] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
75 Fang ZN, Li XH, Lin JJ, Huang SY, Cao QH, Chen ZH, Sun CH, Zhang ZW, Rieder F, Rimola J, Chen MH, Li ZP, Mao R, Feng ST. Magnetisation transfer imaging adds information to conventional MRIs to differentiate inflammatory from fibrotic components of small intestinal strictures in Crohn's disease. Eur Radiol 2020;30:1938-47. [PMID: 31900705 DOI: 10.1007/s00330-019-06594-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
76 Klaassen MAY, Imhann F, Collij V, Fu J, Wijmenga C, Zhernakova A, Dijkstra G, Festen EAM, Gacesa R, Vich Vila A, Weersma RK. Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn's Disease Exacerbations. J Crohns Colitis 2019;13:1439-49. [PMID: 31066440 DOI: 10.1093/ecco-jcc/jjz077] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
77 Flemming S, Luissint AC, Nusrat A, Parkos CA. Analysis of leukocyte transepithelial migration using an in vivo murine colonic loop model. JCI Insight 2018;3:99722. [PMID: 30333307 DOI: 10.1172/jci.insight.99722] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
78 Phillips BE, Garciafigueroa Y, Trucco M, Giannoukakis N. Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease. Front Immunol 2017;8:1279. [PMID: 29075262 DOI: 10.3389/fimmu.2017.01279] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 11.3] [Reference Citation Analysis]
79 Kotze PG, Ma C, Almutairdi A, Panaccione R. Clinical utility of ustekinumab in Crohn's disease. J Inflamm Res. 2018;11:35-47. [PMID: 29445293 DOI: 10.2147/jir.s157358] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
80 Yarani R, Mirza AH, Kaur S, Pociot F. The emerging role of lncRNAs in inflammatory bowel disease. Exp Mol Med 2018;50:1-14. [PMID: 30523244 DOI: 10.1038/s12276-018-0188-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
81 Singh S, Garg SK, Pardi DS, Wang Z, Murad MH, Loftus EV Jr. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn's disease after surgery: a systematic review and network meta-analysis. Gastroenterology 2015; 148: 64-76. quiz e14. [PMID: 25263803 DOI: 10.1053/j.gastro.2014.09.031] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
82 Le V, Crouser ED. Potential immunotherapies for sarcoidosis. Expert Opin Biol Ther 2018;18:399-407. [PMID: 29327613 DOI: 10.1080/14712598.2018.1427727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
83 Ayala-Fontánez N, Soler DC, McCormick TS. Current knowledge on psoriasis and autoimmune diseases. Psoriasis (Auckl) 2016;6:7-32. [PMID: 29387591 DOI: 10.2147/PTT.S64950] [Cited by in Crossref: 22] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
84 Folkerts J, Stadhouders R, Redegeld FA, Tam SY, Hendriks RW, Galli SJ, Maurer M. Effect of Dietary Fiber and Metabolites on Mast Cell Activation and Mast Cell-Associated Diseases. Front Immunol 2018;9:1067. [PMID: 29910798 DOI: 10.3389/fimmu.2018.01067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
85 Sun F, Liang W, Tang K, Hong M, Qian J. Profiling the lncRNA-miRNA-mRNA ceRNA network to reveal potential crosstalk between inflammatory bowel disease and colorectal cancer. PeerJ 2019;7:e7451. [PMID: 31523496 DOI: 10.7717/peerj.7451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
86 Holm TL, Tornehave D, Søndergaard H, Kvist PH, Sondergaard BC, Hansen L, Hermit MB, Holgersen K, Vergo S, Frederiksen KS, Haase C, Lundsgaard D. Evaluating IL-21 as a Potential Therapeutic Target in Crohn's Disease. Gastroenterol Res Pract 2018;2018:5962624. [PMID: 29849593 DOI: 10.1155/2018/5962624] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
87 Duan Y, Liu Y, Li Y. Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn's Disease: A Cohort Study. Gastroenterol Res Pract. 2020;2020:2194382. [PMID: 33014037 DOI: 10.1155/2020/2194382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Hoffmann M, Schwertassek U, Seydel A, Weber K, Hauschildt S, Lehmann J. Therapeutic efficacy of a combined sage and bitter apple phytopharmaceutical in chronic DSS-induced colitis. Sci Rep 2017;7:14214. [PMID: 29079781 DOI: 10.1038/s41598-017-13985-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
89 Ma L, Wang M, Li W, Liu W, Yang H, Jiang Y, Zhu Q. Pilot case-control study to explore the value of intestinal ultrasound in the differentiation of two common diseases involving the ileocecal region: intestinal Behçet's disease and Crohn's disease. Quant Imaging Med Surg 2021;11:3200-8. [PMID: 34249646 DOI: 10.21037/qims-20-1334] [Reference Citation Analysis]
90 Bai J, Yu J, Wang J, Xue B, He N, Tian Y, Yang L, Wang Y, Wang Y, Tang Q. DNA Methylation of miR-122 Aggravates Oxidative Stress in Colitis Targeting SELENBP1 Partially by p65NF-κB Signaling. Oxid Med Cell Longev 2019;2019:5294105. [PMID: 31019652 DOI: 10.1155/2019/5294105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
91 Fotis L, Kourti A, Prountzos S, Alexopoulou E, Papaevangelou V, Fessatou S. Takayasu arteritis in an adolescent with Crohn's disease. Rheumatol Int 2021. [PMID: 33907878 DOI: 10.1007/s00296-021-04869-5] [Reference Citation Analysis]
92 Uzzan M, Ko HM, Mehandru S, Cunningham-Rundles C. Gastrointestinal Disorders Associated with Common Variable Immune Deficiency (CVID) and Chronic Granulomatous Disease (CGD). Curr Gastroenterol Rep 2016;18:17. [PMID: 26951230 DOI: 10.1007/s11894-016-0491-3] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 10.4] [Reference Citation Analysis]
93 Stamatiades GA, Ioannou P, Petrikkos G, Tsioutis C. Fungal infections in patients with inflammatory bowel disease: A systematic review. Mycoses 2018;61:366-76. [PMID: 29453860 DOI: 10.1111/myc.12753] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
94 Lo CH, Khalili H, Song M, Lochhead P, Burke KE, Richter JM, Giovannucci EL, Chan AT, Ananthakrishnan AN. Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021;19:87-95.e4. [PMID: 32142939 DOI: 10.1016/j.cgh.2020.02.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
95 Kiernan MG, Coffey JC, McDermott K, Cotter PD, Cabrera-Rubio R, Kiely PA, Dunne CP. The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis. J Crohns Colitis 2019;13:58-66. [PMID: 30239655 DOI: 10.1093/ecco-jcc/jjy136] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
96 Garber A, Regueiro M. Extraintestinal Manifestations of Inflammatory Bowel Disease: Epidemiology, Etiopathogenesis, and Management. Curr Gastroenterol Rep. 2019;21:31. [PMID: 31098819 DOI: 10.1007/s11894-019-0698-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 10.5] [Reference Citation Analysis]
97 Wittmann Dayagi T, Werner L, Pinsker M, Salamon N, Barschak I, Weiss B, Shouval DS. Mucosal IL-10 and IL-10 receptor expression patterns in paediatric patients with ulcerative colitis. Int J Exp Pathol 2021;102:4-10. [PMID: 33405352 DOI: 10.1111/iep.12382] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Connelly TM, Messaris E. Predictors of recurrence of Crohn’s disease after ileocolectomy: A review. World J Gastroenterol 2014; 20(39): 14393-14406 [PMID: 25339826 DOI: 10.3748/wjg.v20.i39.14393] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
99 Duque Ede A, Munhoz CD. The Pro-inflammatory Effects of Glucocorticoids in the Brain. Front Endocrinol (Lausanne) 2016;7:78. [PMID: 27445981 DOI: 10.3389/fendo.2016.00078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
100 Takahashi K, Nakagawasai O, Nemoto W, Odaira T, Sakuma W, Onogi H, Nishijima H, Furihata R, Nemoto Y, Iwasa H, Tan-No K, Tadano T. Effect of Enterococcus faecalis 2001 on colitis and depressive-like behavior in dextran sulfate sodium-treated mice: involvement of the brain-gut axis. J Neuroinflammation 2019;16:201. [PMID: 31672153 DOI: 10.1186/s12974-019-1580-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
101 Suh SY, An WG. Systems Pharmacological Approach of Pulsatillae Radix on Treating Crohn's Disease. Evid Based Complement Alternat Med 2017;2017:4198035. [PMID: 28659988 DOI: 10.1155/2017/4198035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
102 Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X. Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther 2020;11:345. [PMID: 32771052 DOI: 10.1186/s13287-020-01855-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 26.0] [Reference Citation Analysis]
103 Sun CM, Wu J, Zhang H, Shi G, Chen ZT. Circulating miR-125a but not miR-125b is decreased in active disease status and negatively correlates with disease severity as well as inflammatory cytokines in patients with Crohn’s disease. World J Gastroenterol 2017; 23(44): 7888-7898 [PMID: 29209130 DOI: 10.3748/wjg.v23.i44.7888] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
104 Durayski E, Watte G, Pacini GS, Roman DH, Machado MB, Marchiori E, Hochhegger B, Baldisserotto M. Diffusion-weighted imaging and apparent diffusion coefficient values for evaluating terminal ileitis in patients with Crohn's disease. Radiol Bras 2019;52:361-7. [PMID: 32047329 DOI: 10.1590/0100-3984.2019.0011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Becker HEF, Jamin C, Bervoets L, Boleij A, Xu P, Pierik MJ, Stassen FRM, Savelkoul PHM, Penders J, Jonkers DMAE. Higher Prevalence of Bacteroides fragilis in Crohn's Disease Exacerbations and Strain-Dependent Increase of Epithelial Resistance. Front Microbiol 2021;12:598232. [PMID: 34168621 DOI: 10.3389/fmicb.2021.598232] [Reference Citation Analysis]
106 Darr U, Khan N. Treat to Target in Inflammatory Bowel Disease: An Updated Review of Literature. Curr Treat Options Gastroenterol. 2017;15:116-125. [PMID: 28161818 DOI: 10.1007/s11938-017-0130-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
107 Liu TC, Kern JT, VanDussen KL, Xiong S, Kaiko GE, Wilen CB, Rajala MW, Caruso R, Holtzman MJ, Gao F, McGovern DP, Nunez G, Head RD, Stappenbeck TS. Interaction between smoking and ATG16L1T300A triggers Paneth cell defects in Crohn's disease. J Clin Invest 2018;128:5110-22. [PMID: 30137026 DOI: 10.1172/JCI120453] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 7.7] [Reference Citation Analysis]
108 Kasembeli MM, Bharadwaj U, Robinson P, Tweardy DJ. Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment. Int J Mol Sci 2018;19:E2299. [PMID: 30081609 DOI: 10.3390/ijms19082299] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
109 Bjerrum JT, Wang Y, Hao F, Coskun M, Ludwig C, Günther U, Nielsen OH. Metabonomics of human fecal extracts characterize ulcerative colitis, Crohn's disease and healthy individuals. Metabolomics 2015;11:122-33. [PMID: 25598765 DOI: 10.1007/s11306-014-0677-3] [Cited by in Crossref: 124] [Cited by in F6Publishing: 115] [Article Influence: 17.7] [Reference Citation Analysis]
110 Panpetch W, Hiengrach P, Nilgate S, Tumwasorn S, Somboonna N, Wilantho A, Chatthanathon P, Prueksapanich P, Leelahavanichkul A. Additional Candida albicans administration enhances the severity of dextran sulfate solution induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34. Gut Microbes 2020;11:465-80. [PMID: 31530137 DOI: 10.1080/19490976.2019.1662712] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
111 Tedjo DI, Smolinska A, Savelkoul PH, Masclee AA, van Schooten FJ, Pierik MJ, Penders J, Jonkers DM. The fecal microbiota as a biomarker for disease activity in Crohn's disease. Sci Rep 2016;6:35216. [PMID: 27734914 DOI: 10.1038/srep35216] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
112 Larsson G, Shenoy T, Ramasubramanian R, Balakumaran LK, Småstuen MC, Bjune GA, Moum BA. Routine diagnosis of intestinal tuberculosis and Crohn's disease in Southern India. World J Gastroenterol 2014; 20(17): 5017-5024 [PMID: 24803814 DOI: 10.3748/wjg.v20.i17.5017] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
113 Mishra R, Dhawan P, Srivastava AS, Singh AB. Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World J Stem Cells 2020; 12(10): 1050-1066 [PMID: 33178391 DOI: 10.4252/wjsc.v12.i10.1050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
114 Romagnoni A, Jégou S, Van Steen K, Wainrib G, Hugot JP; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC). Comparative performances of machine learning methods for classifying Crohn Disease patients using genome-wide genotyping data. Sci Rep 2019;9:10351. [PMID: 31316157 DOI: 10.1038/s41598-019-46649-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
115 Freitas TH, Andreoulakis E, Alves GS, Miranda HL, Braga LL, Hyphantis T, Carvalho AF. Associations of sense of coherence with psychological distress and quality of life in inflammatory bowel disease. World J Gastroenterol 2015; 21(21): 6713-6727 [PMID: 26074710 DOI: 10.3748/wjg.v21.i21.6713] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
116 Hahn SA, Bellinghausen I, Trinschek B, Becker C. Translating Treg Therapy in Humanized Mice. Front Immunol 2015;6:623. [PMID: 26697017 DOI: 10.3389/fimmu.2015.00623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
117 Zewde M, Kiyotani K, Park JH, Fang H, Yap KL, Yew PY, Alachkar H, Kato T, Mai TH, Ikeda Y, Matsuda T, Liu X, Ren L, Deng B, Harada M, Nakamura Y. The era of immunogenomics/immunopharmacogenomics. J Hum Genet 2018;63:865-75. [PMID: 29785006 DOI: 10.1038/s10038-018-0468-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
118 Caruana Galizia JP, Cassar PJ. Coexistence of Takayasu Arteritis and Crohn's Disease in a Maltese Patient. Case Rep Rheumatol 2015;2015:384257. [PMID: 26839728 DOI: 10.1155/2015/384257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
119 Althoff P, Schmiegel W, Lang G, Nicolas V, Brechmann T. Creeping Fat Assessed by Small Bowel MRI Is Linked to Bowel Damage and Abdominal Surgery in Crohn's Disease. Dig Dis Sci 2019;64:204-12. [PMID: 30276568 DOI: 10.1007/s10620-018-5303-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
120 Hindryckx P, Laukens D, D'Amico F, Danese S. Unmet Needs in IBD: the Case of Fatigue. Clin Rev Allergy Immunol. 2018;55:368-378. [PMID: 28852978 DOI: 10.1007/s12016-017-8641-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
121 Ge WS, Fan JG. Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysis. World J Gastroenterol 2015; 21(15): 4744-4749 [PMID: 25914486 DOI: 10.3748/wjg.v21.i15.4744] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
122 Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology 2016;5:e118. [PMID: 28090320 DOI: 10.1038/cti.2016.75] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
123 Petersen BS, Fredrich B, Hoeppner MP, Ellinghaus D, Franke A. Opportunities and challenges of whole-genome and -exome sequencing. BMC Genet 2017;18:14. [PMID: 28193154 DOI: 10.1186/s12863-017-0479-5] [Cited by in Crossref: 84] [Cited by in F6Publishing: 79] [Article Influence: 21.0] [Reference Citation Analysis]
124 Shao BZ, Wang SL, Pan P, Yao J, Wu K, Li ZS, Bai Y, Linghu EQ. Targeting NLRP3 Inflammasome in Inflammatory Bowel Disease: Putting out the Fire of Inflammation. Inflammation. 2019;42:1147-1159. [PMID: 30937839 DOI: 10.1007/s10753-019-01008-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 30.0] [Reference Citation Analysis]
125 Moroi R, Shiga H, Endo K, Yamamoto K, Kuroha M, Kanazawa Y, Kakuta Y, Kinouchi Y, Masamune A. Long-Term Prognosis of Japanese Patients with Crohn's Disease Treated by Switching Anti-Tumor Necrosis Factor-α Antibodies. Inflamm Intest Dis 2020;5:11-9. [PMID: 32232050 DOI: 10.1159/000504803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Lourensz K, Jones I. Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: A case report. Int J Surg Case Rep 2015;10:73-5. [PMID: 25805613 DOI: 10.1016/j.ijscr.2015.03.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
127 Rieder F, Bettenworth D, Imai J, Inagaki Y. Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology? Inflamm Intest Dis. 2016;1:41-49. [PMID: 29922656 DOI: 10.1159/000445135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
128 Owczarek D, Rodacki T, Domagała-Rodacka R, Cibor D, Mach T. Diet and nutritional factors in inflammatory bowel diseases. World J Gastroenterol 2016; 22(3): 895-905 [PMID: 26811635 DOI: 10.3748/wjg.v22.i3.895] [Cited by in CrossRef: 105] [Cited by in F6Publishing: 78] [Article Influence: 21.0] [Reference Citation Analysis]
129 Tielbeek JA, Bipat S, Boellaard TN, Nio CY, Stoker J. Training readers to improve their accuracy in grading Crohn's disease activity on MRI. Eur Radiol 2014;24:1059-67. [PMID: 24563158 DOI: 10.1007/s00330-014-3111-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
130 van Erp S, Ercan E, Breedveld P, Brakenhoff L, Ghariq E, Schmid S, Osch MV, van Buchem M, Emmer B, van der Grond J, Wolterbeek R, Hommes D, Fidder H, van der Wee N, Huizinga T, van der Heijde D, Middelkoop H, Ronen I, van der Meulen-de Jong A. Cerebral magnetic resonance imaging in quiescent Crohn’s disease patients with fatigue. World J Gastroenterol 2017; 23(6): 1018-1029 [PMID: 28246475 DOI: 10.3748/wjg.v23.i6.1018] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
131 Wang H, Zuo L, Zhao J, Dong J, Li Y, Gu L, Gong J, Liu Q, Zhu W. Impact of Preoperative Exclusive Enteral Nutrition on Postoperative Complications and Recurrence After Bowel Resection in Patients with Active Crohn's Disease. World J Surg 2016;40:1993-2000. [PMID: 26940580 DOI: 10.1007/s00268-016-3488-z] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
132 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Decrease in Mucosal IL17A, IFNγ and IL10 Expressions in Active Crohn's Disease Patients Treated with High-Dose Vitamin Alone or Combined with Infliximab. Nutrients 2020;12:E3699. [PMID: 33266022 DOI: 10.3390/nu12123699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Xiao CX, Xiao JJ, Xu HZ, Wang HH, Chen X, Liu YS, Li P, Shi Y, Nie YZ, Li S, Wu KC, Liu ZJ, Ren JL, Guleng B. Exome sequencing identifies novel compound heterozygous IFNA4 and IFNA10 mutations as a cause of impaired function in Crohn's disease patients. Sci Rep 2015;5:10514. [PMID: 26000985 DOI: 10.1038/srep10514] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
134 Bourgonje AR, von Martels JZH, de Vos P, Faber KN, Dijkstra G. Increased fecal calprotectin levels in Crohn's disease correlate with elevated serum Th1- and Th17-associated cytokines. PLoS One 2018;13:e0193202. [PMID: 29466406 DOI: 10.1371/journal.pone.0193202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
135 Jeong EM, Son YH, Choi Y, Kim JH, Lee JH, Cho SY, Kim IG. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp Mol Med 2016;48:e267. [PMID: 27811936 DOI: 10.1038/emm.2016.95] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
136 Mantarro A, Scalise P, Guidi E, Neri E. Magnetic resonance enterography in Crohn’s disease: How we do it and common imaging findings. World J Radiol 2017; 9(2): 46-54 [PMID: 28298964 DOI: 10.4329/wjr.v9.i2.46] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
137 Gwon Y, Mo M, Chen MH, Chi Z, Li J, Xia AH, Ibrahim JG. Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. Stat Med 2020. [PMID: 32166784 DOI: 10.1002/sim.8518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017;14:22-31. [PMID: 27729659 DOI: 10.1038/nrgastro.2016.155] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
139 Antoniou E, Margonis GA, Angelou A, Pikouli A, Argiri P, Karavokyros I, Papalois A, Pikoulis E. The TNBS-induced colitis animal model: An overview. Ann Med Surg (Lond). 2016;11:9-15. [PMID: 27656280 DOI: 10.1016/j.amsu.2016.07.019] [Cited by in Crossref: 108] [Cited by in F6Publishing: 108] [Article Influence: 21.6] [Reference Citation Analysis]
140 Yoo SW, Oh G, Ahn JC, Chung E. Non-Oncologic Applications of Nanomedicine-Based Phototherapy. Biomedicines 2021;9:113. [PMID: 33504015 DOI: 10.3390/biomedicines9020113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
141 Chew TS, Mansfield JC. Can faecal calprotectin predict relapse in inflammatory bowel disease: A mini review. Frontline Gastroenterol. 2018;9:23-28. [PMID: 29484157 DOI: 10.1136/flgastro-2016-100686] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
142 Bjerrum JT, Steenholdt C, Ainsworth M, Nielsen OH, Reed MA, Atkins K, Günther UL, Hao F, Wang Y. Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease. BMC Med 2017;15:184. [PMID: 29032767 DOI: 10.1186/s12916-017-0949-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
143 Unger LW, Argeny S, Stift A, Yang Y, Karall A, Freilinger T, Müller C, Bergmann M, Stift J, Riss S. Mesenteric granulomas independently predict long-term risk of surgical recurrence in Crohn's disease. Colorectal Dis 2020;22:170-7. [PMID: 31393663 DOI: 10.1111/codi.14814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Singh V, Kumar M, San Yeoh B, Xiao X, Saha P, Kennett MJ, Vijay-Kumar M. Inhibition of Interleukin-10 Signaling Induces Microbiota-dependent Chronic Colitis in Apolipoprotein E Deficient Mice. Inflamm Bowel Dis 2016;22:841-52. [PMID: 26891260 DOI: 10.1097/MIB.0000000000000699] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
145 Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES. Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J 2017;5:762-72. [PMID: 29026590 DOI: 10.1177/2050640616672953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
146 Eun CS, Kwak MJ, Han DS, Lee AR, Park DI, Yang SK, Kim YS, Kim JF. Does the intestinal microbial community of Korean Crohn's disease patients differ from that of western patients? BMC Gastroenterol 2016;16:28. [PMID: 26922889 DOI: 10.1186/s12876-016-0437-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
147 Ribeiro A, Pontis S, Mengatto L, Armirotti A, Chiurchiù V, Capurro V, Fiasella A, Nuzzi A, Romeo E, Moreno-Sanz G, Maccarrone M, Reggiani A, Tarzia G, Mor M, Bertozzi F, Bandiera T, Piomelli D. A Potent Systemically Active N-Acylethanolamine Acid Amidase Inhibitor that Suppresses Inflammation and Human Macrophage Activation. ACS Chem Biol 2015;10:1838-46. [PMID: 25874594 DOI: 10.1021/acschembio.5b00114] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 9.0] [Reference Citation Analysis]
148 Hedjoudje A, Cheurfa C, Briquez C, Zhang A, Koch S, Vuitton L. rs2476601 polymorphism in PTPN22 is associated with Crohn's disease but not with ulcerative colitis: a meta-analysis of 16,838 cases and 13,356 controls. Ann Gastroenterol 2017;30:197-208. [PMID: 28243041 DOI: 10.20524/aog.2017.0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
149 Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, Eckmann L, Barrett KE, Chang JT, Sandborn WJ. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol 2019;17:2634-43. [PMID: 31009791 DOI: 10.1016/j.cgh.2019.04.040] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
150 Nielsen OH, LaCasse EC. How genetic testing can lead to targeted management of XIAP deficiency-related inflammatory bowel disease. Genet Med 2017;19:133-43. [PMID: 27416006 DOI: 10.1038/gim.2016.82] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
151 Kim HS, Chung S, Song MY, Lim C, Shin H, Hur J, Kwon H, Suh YG, Kim EH, Shin D, Kim SH. Efficient and Divergent Enantioselective Syntheses of DHPVs and Anti-Inflammatory Effect on IEC-6 Cells. Molecules 2020;25:E2215. [PMID: 32397326 DOI: 10.3390/molecules25092215] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Andreoletti G, Ashton JJ, Coelho T, Willis C, Haggarty R, Gibson J, Holloway J, Batra A, Afzal NA, Beattie RM, Ennis S. Exome analysis of patients with concurrent pediatric inflammatory bowel disease and autoimmune disease. Inflamm Bowel Dis 2015;21:1229-36. [PMID: 25895113 DOI: 10.1097/MIB.0000000000000381] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
153 Chewchuk S, Jahan S, Lohnes D. Cdx2 regulates immune cell infiltration in the intestine. Sci Rep 2021;11:15841. [PMID: 34349205 DOI: 10.1038/s41598-021-95412-w] [Reference Citation Analysis]
154 Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P. Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers. Crohns Colitis 360 2020;2:otaa003. [PMID: 32551441 DOI: 10.1093/crocol/otaa003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
155 Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal stricture in Crohn’s disease. Intest Res. 2015;13:19-26. [PMID: 25691840 DOI: 10.5217/ir.2015.13.1.19] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
156 Zhen Y, Zhang H. NLRP3 Inflammasome and Inflammatory Bowel Disease. Front Immunol. 2019;10:276. [PMID: 30873162 DOI: 10.3389/fimmu.2019.00276] [Cited by in Crossref: 81] [Cited by in F6Publishing: 81] [Article Influence: 40.5] [Reference Citation Analysis]
157 Keir M, Yi Y, Lu T, Ghilardi N. The role of IL-22 in intestinal health and disease. J Exp Med 2020;217:e20192195. [PMID: 32997932 DOI: 10.1084/jem.20192195] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
158 Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J. Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study. J Crohns Colitis 2018;12:1170-9. [PMID: 30032288 DOI: 10.1093/ecco-jcc/jjy099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
159 Lu ZJ, Wu JJ, Jiang WL, Xiao JH, Tao KZ, Ma L, Zheng P, Wan R, Wang XP. MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression. World J Gastroenterol 2017; 23(6): 976-985 [PMID: 28246471 DOI: 10.3748/wjg.v23.i6.976] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
160 Oh EH, Oh K, Han M, Seo H, Chang K, Lee SH, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors. PLoS One 2017;12:e0177479. [PMID: 28542298 DOI: 10.1371/journal.pone.0177479] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
161 Bokemeyer A, Tepasse PR, Quill L, Lenz P, Rijcken E, Vieth M, Ding N, Ketelhut S, Rieder F, Kemper B, Bettenworth D. Quantitative Phase Imaging Using Digital Holographic Microscopy Reliably Assesses Morphology and Reflects Elastic Properties of Fibrotic Intestinal Tissue. Sci Rep 2019;9:19388. [PMID: 31852983 DOI: 10.1038/s41598-019-56045-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
162 Ramos-Rivers C, Regueiro M, Vargas EJ, Szigethy E, Schoen RE, Dunn M, Watson AR, Schwartz M, Swoger J, Baidoo L, Barrie A, Dudekula A, Youk AO, Binion DG. Association between telephone activity and features of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:986-94.e1. [PMID: 24262938 DOI: 10.1016/j.cgh.2013.11.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
163 Wang R, Gu X, Dai W, Ye J, Lu F, Chai Y, Fan G, Gonzalez FJ, Duan G, Qi Y. A lipidomics investigation into the intervention of celastrol in experimental colitis. Mol Biosyst 2016;12:1436-44. [PMID: 27021137 DOI: 10.1039/c5mb00864f] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
164 Jeengar MK, Thummuri D, Magnusson M, Naidu VGM, Uppugunduri S. Uridine Ameliorates Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. Sci Rep 2017;7:3924. [PMID: 28634361 DOI: 10.1038/s41598-017-04041-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
165 Ratsimandresy RA, Indramohan M, Dorfleutner A, Stehlik C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell Mol Immunol 2017;14:127-42. [PMID: 27524110 DOI: 10.1038/cmi.2016.35] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 12.6] [Reference Citation Analysis]
166 Seishima J, Iida N, Kitamura K, Yutani M, Wang Z, Seki A, Yamashita T, Sakai Y, Honda M, Yamashita T, Kagaya T, Shirota Y, Fujinaga Y, Mizukoshi E, Kaneko S. Gut-derived Enterococcus faecium from ulcerative colitis patients promotes colitis in a genetically susceptible mouse host. Genome Biol 2019;20:252. [PMID: 31767028 DOI: 10.1186/s13059-019-1879-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
167 Chew TS, O'Shea NR, Sewell GW, Oehlers SH, Mulvey CM, Crosier PS, Godovac-Zimmermann J, Bloom SL, Smith AM, Segal AW. Optineurin deficiency in mice contributes to impaired cytokine secretion and neutrophil recruitment in bacteria-driven colitis. Dis Model Mech 2015;8:817-29. [PMID: 26044960 DOI: 10.1242/dmm.020362] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
168 Stappenbeck TS, McGovern DPB. Paneth Cell Alterations in the Development and Phenotype of Crohn's Disease. Gastroenterology 2017;152:322-6. [PMID: 27729212 DOI: 10.1053/j.gastro.2016.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
169 Pontone S, Cicerone C, Magliocca FM, Vernia P. Super-slim endoscopy, in a patient with a Crohn's ileocecal valve stricture, for assessment of mucosal healing. Tech Coloproctol 2016;20:259-61. [PMID: 26886934 DOI: 10.1007/s10151-016-1441-7] [Reference Citation Analysis]
170 Loganes C, Valencic E, Pin A, Marini E, Martelossi S, Naviglio S, De Leo L, Not T, Monasta L, Tommasini A, Marcuzzi A. Ex vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease. World J Gastroenterol 2016; 22(44): 9734-9743 [PMID: 27956797 DOI: 10.3748/wjg.v22.i44.9734] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
171 Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Korzenik JR, Fuchs CS, Willett WC, Richter JM, Chan AT. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology. 2013;145:970-977. [PMID: 23912083 DOI: 10.1053/j.gastro.2013.07.050] [Cited by in Crossref: 290] [Cited by in F6Publishing: 234] [Article Influence: 36.3] [Reference Citation Analysis]
172 Bao CH, Zhao JM, Liu HR, Lu Y, Zhu YF, Shi Y, Weng ZJ, Feng H, Guan X, Li J, Chen WF, Wu LY, Jin XM, Dou CZ, Wu HG. Randomized controlled trial: Moxibustion and acupuncture for the treatment of Crohn’s disease. World J Gastroenterol 2014; 20(31): 11000-11011 [PMID: 25152604 DOI: 10.3748/wjg.v20.i31.11000] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
173 Elleisy N, Rohde S, Huth A, Gittel N, Glass Ä, Möller S, Lamprecht G, Schäffler H, Jaster R. Genetic association analysis of CLEC5A and CLEC7A gene single-nucleotide polymorphisms and Crohn’s disease. World J Gastroenterol 2020; 26(18): 2194-2202 [PMID: 32476786 DOI: 10.3748/wjg.v26.i18.2194] [Reference Citation Analysis]
174 Sun Y, Li L, Xia Y, Li W, Wang K, Wang L, Miao Y, Ma S. The gut microbiota heterogeneity and assembly changes associated with the IBD. Sci Rep 2019;9:440. [PMID: 30679676 DOI: 10.1038/s41598-018-37143-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
175 Wu XW, Ji HZ, Wang FY. Meta-analysis of ciprofloxacin in treatment of Crohn's disease. Biomed Rep 2015;3:70-4. [PMID: 25469250 DOI: 10.3892/br.2014.368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
176 Xu P, Elizalde M, Masclee A, Pierik M, Jonkers D. Corticosteroid enhances epithelial barrier function in intestinal organoids derived from patients with Crohn's disease. J Mol Med (Berl) 2021;99:805-15. [PMID: 33575854 DOI: 10.1007/s00109-021-02045-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Belarif L, Danger R, Kermarrec L, Nerrière-Daguin V, Pengam S, Durand T, Mary C, Kerdreux E, Gauttier V, Kucik A, Thepenier V, Martin JC, Chang C, Rahman A, Guen NS, Braudeau C, Abidi A, David G, Malard F, Takoudju C, Martinet B, Gérard N, Neveu I, Neunlist M, Coron E, MacDonald TT, Desreumaux P, Mai HL, Le Bas-Bernardet S, Mosnier JF, Merad M, Josien R, Brouard S, Soulillou JP, Blancho G, Bourreille A, Naveilhan P, Vanhove B, Poirier N. IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest 2019;129:1910-25. [PMID: 30939120 DOI: 10.1172/JCI121668] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 16.5] [Reference Citation Analysis]
178 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases. J Clin Med 2021;10:1515. [PMID: 33916465 DOI: 10.3390/jcm10071515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Ruemmele FM, Rosh J, Faubion WA, Dubinsky MC, Turner D, Lazar A, Eichner S, Maa JF, Alperovich G, Robinson AM, Hyams JS. Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2. J Crohns Colitis. 2018;12:1249-1254. [PMID: 29939254 DOI: 10.1093/ecco-jcc/jjy087] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
180 Francescone R, Hou V, Grivennikov SI. Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015;21:409-418. [PMID: 25563695 DOI: 10.1097/mib.0000000000000236] [Cited by in Crossref: 136] [Cited by in F6Publishing: 78] [Article Influence: 22.7] [Reference Citation Analysis]
181 Timmer A, de Sordi D, Menke E, Peplies J, Claßen M, Koletzko S, Otto-Sobotka F. Modeling determinants of satisfaction with health care in youth with inflammatory bowel disease: a cross-sectional survey. Clin Epidemiol 2018;10:1289-305. [PMID: 30310323 DOI: 10.2147/CLEP.S165554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
182 Pellegrini C, Fornai M, Colucci R, Benvenuti L, D’Antongiovanni V, Natale G, Fulceri F, Giorgis M, Marini E, Gastaldi S, Bertinaria M, Blandizzi C, Antonioli L. A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Front Pharmacol 2018;9:1405. [PMID: 30559669 DOI: 10.3389/fphar.2018.01405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
183 Neurath MF. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017;14:269-278. [PMID: 28144028 DOI: 10.1038/nrgastro.2016.208] [Cited by in Crossref: 214] [Cited by in F6Publishing: 209] [Article Influence: 53.5] [Reference Citation Analysis]
184 Reif S, Elbaum-Shiff Y, Koroukhov N, Shilo I, Musseri M, Golan-Gerstl R. Cow and Human Milk-Derived Exosomes Ameliorate Colitis in DSS Murine Model. Nutrients 2020;12:E2589. [PMID: 32858892 DOI: 10.3390/nu12092589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
185 Mikulski Z, Johnson R, Shaked I, Kim G, Nowyhed H, Goodman W, Chodaczek G, Pizarro TT, Cominelli F, Ley K. SAMP1/YitFc mice develop ileitis via loss of CCL21 and defects in dendritic cell migration. Gastroenterology 2015;148:783-793.e5. [PMID: 25620669 DOI: 10.1053/j.gastro.2015.01.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
186 Rivas MA, Avila BE, Koskela J, Huang H, Stevens C, Pirinen M, Haritunians T, Neale BM, Kurki M, Ganna A, Graham D, Glaser B, Peter I, Atzmon G, Barzilai N, Levine AP, Schiff E, Pontikos N, Weisburd B, Lek M, Karczewski KJ, Bloom J, Minikel EV, Petersen BS, Beaugerie L, Seksik P, Cosnes J, Schreiber S, Bokemeyer B, Bethge J, Heap G, Ahmad T, Plagnol V, Segal AW, Targan S, Turner D, Saavalainen P, Farkkila M, Kontula K, Palotie A, Brant SR, Duerr RH, Silverberg MS, Rioux JD, Weersma RK, Franke A, Jostins L, Anderson CA, Barrett JC, MacArthur DG, Jalas C, Sokol H, Xavier RJ, Pulver A, Cho JH, McGovern DPB, Daly MJ; International IBD Genetics Consortium., NIDDK IBD Genetics Consortium., T2D-GENES Consortium. Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. PLoS Genet 2018;14:e1007329. [PMID: 29795570 DOI: 10.1371/journal.pgen.1007329] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
187 Alves de Almeida AC, de-Faria FM, Dunder RJ, Manzo LP, Souza-Brito AR, Luiz-Ferreira A. Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease. Evid Based Complement Alternat Med 2017;2017:8528210. [PMID: 28191024 DOI: 10.1155/2017/8528210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
188 Sebastián VP, Salazar GA, Coronado-Arrázola I, Schultz BM, Vallejos OP, Berkowitz L, Álvarez-Lobos MM, Riedel CA, Kalergis AM, Bueno SM. Heme Oxygenase-1 as a Modulator of Intestinal Inflammation Development and Progression. Front Immunol 2018;9:1956. [PMID: 30258436 DOI: 10.3389/fimmu.2018.01956] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
189 Yu L, Yang X, Xia L, Zhong J, Ge W, Wu J, Liu H, Liu F, Liu Z. Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm 2015;2015:793764. [PMID: 25873771 DOI: 10.1155/2015/793764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
190 Schoultz M, Atherton IM, Hubbard G, Watson AJ. The use of mindfulness-based cognitive therapy for improving quality of life for inflammatory bowel disease patients: study protocol for a pilot randomised controlled trial with embedded process evaluation. Trials 2013;14:431. [PMID: 24341333 DOI: 10.1186/1745-6215-14-431] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
191 Currò D, Ianiro G, Pecere S, Bibbò S, Cammarota G. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. Br J Pharmacol 2017;174:1426-49. [PMID: 27696378 DOI: 10.1111/bph.13632] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 12.6] [Reference Citation Analysis]
192 Benmoussa A, Diallo I, Salem M, Michel S, Gilbert C, Sévigny J, Provost P. Concentrates of two subsets of extracellular vesicles from cow's milk modulate symptoms and inflammation in experimental colitis. Sci Rep 2019;9:14661. [PMID: 31601878 DOI: 10.1038/s41598-019-51092-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
193 Yang Y, Jobin C. Microbial imbalance and intestinal pathologies: connections and contributions. Dis Model Mech. 2014;7:1131-1142. [PMID: 25256712 DOI: 10.1242/dmm.016428] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
194 Bavaro DF, Ingravallo G, Signorile F, Fortarezza F, Di Gennaro F, Angarano G, Saracino A. Splenic abscesses as a first manifestation of Crohn's disease: a case report. BMC Gastroenterol 2019;19:144. [PMID: 31416435 DOI: 10.1186/s12876-019-1066-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
195 Zwicker S, Martinez GL, Bosma M, Gerling M, Clark R, Majster M, Söderman J, Almer S, Boström EA. Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin Sci (Lond) 2015;129:281-90. [PMID: 25896238 DOI: 10.1042/CS20150176] [Cited by in Crossref: 53] [Cited by in F6Publishing: 26] [Article Influence: 8.8] [Reference Citation Analysis]
196 Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J 2020;287:3967-88. [PMID: 32003126 DOI: 10.1111/febs.15236] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
197 Ananthakrishnan AN, Khalili H, Konijeti GG, Higuchi LM, de Silva P, Fuchs CS, Richter JM, Schernhammer ES, Chan AT. Sleep duration affects risk for ulcerative colitis: a prospective cohort study. Clin Gastroenterol Hepatol. 2014;12:1879-1886. [PMID: 24780288 DOI: 10.1016/j.cgh.2014.04.021] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.9] [Reference Citation Analysis]
198 Holko P, Kawalec P, Pilc A. Impact of Biologic Treatment of Crohn's Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland. Front Pharmacol 2018;9:621. [PMID: 29942260 DOI: 10.3389/fphar.2018.00621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
199 Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H. Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease. Gastroenterol Res Pract 2015;2015:231243. [PMID: 26064087 DOI: 10.1155/2015/231243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
200 Lopez J, Konijeti GG, Nguyen DD, Sauk J, Yajnik V, Ananthakrishnan AN. Natural history of Crohn's disease following total colectomy and end ileostomy. Inflamm Bowel Dis 2014;20:1236-41. [PMID: 24859297 DOI: 10.1097/MIB.0000000000000072] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
201 Xiao N, Liu F, Zhou G, Sun M, Ai F, Liu Z. Food-specific IgGs Are Highly Increased in the Sera of Patients with Inflammatory Bowel Disease and Are Clinically Relevant to the Pathogenesis. Intern Med 2018;57:2787-98. [PMID: 29780153 DOI: 10.2169/internalmedicine.9377-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
202 Ahmed I, Roy BC, Khan SA, Septer S, Umar S. Microbiome, Metabolome and Inflammatory Bowel Disease. Microorganisms. 2016;4:20. [PMID: 27681914 DOI: 10.3390/microorganisms4020020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 13.0] [Reference Citation Analysis]
203 Bjerrum JT, Rantalainen M, Wang Y, Olsen J, Nielsen OH. Integration of transcriptomics and metabonomics: improving diagnostics, biomarker identification and phenotyping in ulcerative colitis. Metabolomics. 2014;10:280-290. [PMID: 25221466 DOI: 10.1007/s11306-013-0580-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
204 Wang Y, Mao Y, Zhang J, Shi G, Cheng L, Lin Y, Li Y, Zhang X, Zhang Y, Chen X, Deng J, Su X, Dai L, Yang Y, Zhang S, Yu D, Wei Y, Deng H. IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells. J Cell Mol Med 2018;22:1014-25. [PMID: 29193791 DOI: 10.1111/jcmm.13428] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
205 Gibiino G, Sartini A, Gitto S, Binda C, Sbrancia M, Coluccio C, Sambri V, Fabbri C. The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:2772. [PMID: 34444932 DOI: 10.3390/nu13082772] [Reference Citation Analysis]
206 Borecki K, Zawada I, Salkić NN, Karakiewicz B, Adler G. Relationship between the IL23R SNPs and Crohn's Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study. Int J Environ Res Public Health 2019;16:E1551. [PMID: 31052515 DOI: 10.3390/ijerph16091551] [Reference Citation Analysis]
207 Oliveira MC, Elias JB, Moraes DA, Simões BP, Rodrigues M, Ribeiro AAF, Piron-Ruiz L, Ruiz MA, Hamerschlak N. A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther 2021;43:65-86. [PMID: 32418777 DOI: 10.1016/j.htct.2020.03.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
208 Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, Basic M, Dupont A, Hornef M, von Bergen M, Bleich A, Haller D. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. Gut. 2016;65:225-237. [PMID: 25887379 DOI: 10.1136/gutjnl-2015-309333] [Cited by in Crossref: 188] [Cited by in F6Publishing: 168] [Article Influence: 31.3] [Reference Citation Analysis]
209 Jin Y, Blikslager AT. The Regulation of Intestinal Mucosal Barrier by Myosin Light Chain Kinase/Rho Kinases. Int J Mol Sci 2020;21:E3550. [PMID: 32443411 DOI: 10.3390/ijms21103550] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
210 Moroi R, Endo K, Yamamoto K, Naito T, Onodera M, Kuroha M, Kanazawa Y, Kimura T, Kakuta Y, Masamune A, Kinouchi Y, Shimosegawa T. Long-term prognosis of Japanese patients with biologic-naïve Crohn's disease treated with anti-tumor necrosis factor-α antibodies. Intest Res 2019;17:94-106. [PMID: 30508475 DOI: 10.5217/ir.2018.00048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
211 Nonnecke EB, Castillo PA, Dugan AE, Almalki F, Underwood MA, De La Motte CA, Yuan W, Lu W, Shen B, Johansson MEV, Kiessling LL, Hollox EJ, Lönnerdal B, Bevins CL. Human intelectin-1 (ITLN1) genetic variation and intestinal expression. Sci Rep 2021;11:12889. [PMID: 34145348 DOI: 10.1038/s41598-021-92198-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Zamani S, Zali MR, Aghdaei HA, Sechi LA, Niegowska M, Caggiu E, Keshavarz R, Mosavari N, Feizabadi MM. Mycobacterium avium subsp. paratuberculosis and associated risk factors for inflammatory bowel disease in Iranian patients. Gut Pathog 2017;9:1. [PMID: 28053669 DOI: 10.1186/s13099-016-0151-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
213 Yadav V, Mai Y, McCoubrey LE, Wada Y, Tomioka M, Kawata S, Charde S, Basit AW. 5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease. Biomedicines 2021;9:578. [PMID: 34065300 DOI: 10.3390/biomedicines9050578] [Reference Citation Analysis]
214 Thurner L, Stöger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M. Proinflammatory progranulin antibodies in inflammatory bowel diseases. Dig Dis Sci 2014;59:1733-42. [PMID: 24591016 DOI: 10.1007/s10620-014-3089-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
215 Ng CH, Chin YH, Lin SY, Koh JWH, Lieske B, Koh FH, Chong CS, Foo FJ. Kono-S anastomosis for Crohn's disease: a systemic review, meta-analysis, and meta-regression. Surg Today 2021;51:493-501. [PMID: 32894346 DOI: 10.1007/s00595-020-02130-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
216 Liu L, Zhao C, Yang Y, Kong X, Shao T, Ren L, Zhuang X, Yin B, Dryden G, McClain C, Luan W, Feng W. Fibroblast Growth Factor 21 Deficiency Attenuates Experimental Colitis-Induced Adipose Tissue Lipolysis. Gastroenterol Res Pract 2017;2017:3089378. [PMID: 28584524 DOI: 10.1155/2017/3089378] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
217 Shafran I, Burgunder P, Wei D, Young HE, Klein G, Burnett BP. Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin. Therap Adv Gastroenterol 2015;8:331-9. [PMID: 26557889 DOI: 10.1177/1756283X15593693] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
218 Bokemeyer A, Tentrop N, Barth PJ, Lenze F, Hengst K, Kleinheinz J, Bettenworth D. Successful treatment of oral Crohn's disease by anti-TNF-alpha dose escalation - a case report. BMC Gastroenterol 2018;18:88. [PMID: 29914414 DOI: 10.1186/s12876-018-0818-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
219 Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. Drug Des Devel Ther. 2014;9:147-154. [PMID: 25552903 DOI: 10.2147/dddt.s50348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
220 Jarry A, Bossard C, Droy-Dupré L, Volteau C, Bourreille A, Meurette G, Mosnier JF, Laboisse CL. Heterogeneity of subordination of the IL-18/IFN-γ axis to caspase-1 among patients with Crohn's disease. Lab Invest 2015;95:1207-17. [PMID: 26168332 DOI: 10.1038/labinvest.2015.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
221 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Diabetes and the risk of infections with immunomodulator therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2015;41:1141-8. [PMID: 25864945 DOI: 10.1111/apt.13195] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
222 Zhou G, Yu L, Yang W, Wu W, Fang L, Liu Z. Blockade of PLD2 Ameliorates Intestinal Mucosal Inflammation of Inflammatory Bowel Disease. Mediators Inflamm 2016;2016:2543070. [PMID: 27721573 DOI: 10.1155/2016/2543070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
223 Rabbi MF, Eissa N, Munyaka PM, Kermarrec L, Elgazzar O, Khafipour E, Bernstein CN, Ghia JE. Reactivation of Intestinal Inflammation Is Suppressed by Catestatin in a Murine Model of Colitis via M1 Macrophages and Not the Gut Microbiota. Front Immunol 2017;8:985. [PMID: 28871257 DOI: 10.3389/fimmu.2017.00985] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
224 Abbass M, Cepek J, Parker CE, Nguyen TM, MacDonald JK, Feagan BG, Khanna R, Jairath V. Adalimumab for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;2019. [PMID: 31742665 DOI: 10.1002/14651858.CD012878.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
225 Li J, Li P, Bai J, Lyu H, Li Y, Yang H, Shen B, Qian JM. Discriminating potential of extraintestinal systemic manifestations and colonoscopic features in Chinese patients with intestinal Behçet's disease and Crohn's disease. Chin Med J (Engl) 2015;128:233-8. [PMID: 25591568 DOI: 10.4103/0366-6999.149213] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
226 Silva I, Pinto R, Mateus V. Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis. J Clin Med 2019;8:E1574. [PMID: 31581545 DOI: 10.3390/jcm8101574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
227 Gutiérrez A, Rivero M, Martín-Arranz MD, García Sánchez V, Castro M, Barrio J, de Francisco R, Barreiro-de Acosta M, Juliá B, Cea-Calvo L, Romero C, Borruel Sainz N, Domènech E. Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. Gastroenterol Rep (Oxf) 2019;7:168-75. [PMID: 31217980 DOI: 10.1093/gastro/goz010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
228 Luján-Sanchis M, Sanchis-Artero L, Larrey-Ruiz L, Peño-Muñoz L, Núñez-Martínez P, Castillo-López G, González-González L, Clemente CB, Albert Antequera C, Durá-Ayet A, Sempere-Garcia-Argüelles J. Current role of capsule endoscopy in Crohn’s disease. World J Gastrointest Endosc 2016; 8(17): 572-583 [PMID: 27668067 DOI: 10.4253/wjge.v8.i17.572] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
229 Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. J Crohns Colitis 2020;14:1066-73. [PMID: 32060515 DOI: 10.1093/ecco-jcc/jjaa027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
230 Irving P, Barrett K, Tang D, Nijher M, de Lusignan S. Common infections, mental health problems and healthcare use in people with inflammatory bowel disease: a cohort study protocol. Evid Based Ment Health 2021;24:82-7. [PMID: 32943436 DOI: 10.1136/ebmental-2020-300167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
231 Flemming S, Luissint AC, Kusters DHM, Raya-Sandino A, Fan S, Zhou DW, Hasegawa M, Garcia-Hernandez V, García AJ, Parkos CA, Nusrat A. Desmocollin-2 promotes intestinal mucosal repair by controlling integrin-dependent cell adhesion and migration. Mol Biol Cell 2020;31:407-18. [PMID: 31967937 DOI: 10.1091/mbc.E19-12-0692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
232 Andersen V, Möller S, Jensen PB, Møller FT, Green A. Caesarean Delivery and Risk of Chronic Inflammatory Diseases (Inflammatory Bowel Disease, Rheumatoid Arthritis, Coeliac Disease, and Diabetes Mellitus): A Population Based Registry Study of 2,699,479 Births in Denmark During 1973-2016. Clin Epidemiol 2020;12:287-93. [PMID: 32210632 DOI: 10.2147/CLEP.S229056] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 17.0] [Reference Citation Analysis]
233 Marcuzzi A, Bianco AM, Girardelli M, Tommasini A, Martelossi S, Monasta L, Crovella S. Genetic and functional profiling of Crohn's disease: autophagy mechanism and susceptibility to infectious diseases. Biomed Res Int 2013;2013:297501. [PMID: 23738324 DOI: 10.1155/2013/297501] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
234 Sugimoto MA, Sousa LP, Pinho V, Perretti M, Teixeira MM. Resolution of Inflammation: What Controls Its Onset? Front Immunol 2016;7:160. [PMID: 27199985 DOI: 10.3389/fimmu.2016.00160] [Cited by in Crossref: 214] [Cited by in F6Publishing: 213] [Article Influence: 42.8] [Reference Citation Analysis]
235 Coretti L, Natale A, Cuomo M, Florio E, Keller S, Lembo F, Chiariotti L, Pero R. The Interplay between Defensins and Microbiota in Crohn's Disease. Mediators Inflamm 2017;2017:8392523. [PMID: 28246439 DOI: 10.1155/2017/8392523] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
236 O'Connell L, Winter DC, Aherne CM. The Role of Organoids as a Novel Platform for Modeling of Inflammatory Bowel Disease. Front Pediatr 2021;9:624045. [PMID: 33681101 DOI: 10.3389/fped.2021.624045] [Reference Citation Analysis]
237 Crowley E, Warner N, Pan J, Khalouei S, Elkadri A, Fiedler K, Foong J, Turinsky AL, Bronte-Tinkew D, Zhang S, Hu J, Tian D, Li D, Horowitz J, Siddiqui I, Upton J, Roifman CM, Church PC, Wall DA, Ramani AK, Kotlarz D, Klein C, Uhlig H, Snapper SB, Gonzaga-Jauregui C, Paterson AD, McGovern DPB, Brudno M, Walters TD, Griffiths AM, Muise AM. Prevalence and Clinical Features of Inflammatory Bowel Diseases Associated With Monogenic Variants, Identified by Whole-Exome Sequencing in 1000 Children at a Single Center. Gastroenterology 2020;158:2208-20. [PMID: 32084423 DOI: 10.1053/j.gastro.2020.02.023] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
238 Schäfer AO. [Perianal inflammatory diseases : Classification and imaging]. Radiologe 2018;58:344-54. [PMID: 29464273 DOI: 10.1007/s00117-018-0368-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
239 Cougnoux A, Movassaghi M, Picache JA, Iben JR, Navid F, Salman A, Martin K, Farhat NY, Cluzeau C, Tseng WC, Burkert K, Sojka C, Wassif CA, Cawley NX, Bonnet R, Porter FD. Gastrointestinal Tract Pathology in a BALB/c Niemann-Pick Disease Type C1 Null Mouse Model. Dig Dis Sci 2018;63:870-80. [PMID: 29357083 DOI: 10.1007/s10620-018-4914-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
240 De Francesco F, Romano M, Zarantonello L, Ruffolo C, Neri D, Bassi N, Giordano A, Zanus G, Ferraro GA, Cillo U. The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies. Cancer Biol Ther. 2016;17:889-898. [PMID: 27414952 DOI: 10.1080/15384047.2016.1210741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
241 Chen H, Yang H, Deng J, Fan D. Ginsenoside Rk3 Ameliorates Obesity-Induced Colitis by Regulating of Intestinal Flora and the TLR4/NF-κB Signaling Pathway in C57BL/6 Mice. J Agric Food Chem 2021;69:3082-93. [PMID: 33621094 DOI: 10.1021/acs.jafc.0c07805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
242 Souza DG, Senchenkova EY, Russell J, Granger DN. MyD88 mediates the protective effects of probiotics against the arteriolar thrombosis and leukocyte recruitment associated with experimental colitis. Inflamm Bowel Dis 2015;21:888-900. [PMID: 25738377 DOI: 10.1097/MIB.0000000000000331] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
243 Ge J, Zhu L, Zhou J, Li G, Li Y, Li S, Wu Z, Rong J, Yuan H, Liu Y, Chi Q, Piao D, Zhao Y, Cui B. Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese. J Cancer Res Clin Oncol 2015;141:1533-44. [PMID: 25604582 DOI: 10.1007/s00432-015-1915-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
244 Dong J, Wang H, Zhao J, Sun J, Zhang T, Zuo L, Zhu W, Gong J, Li Y, Gu L, Li J. SEW2871 protects from experimental colitis through reduced epithelial cell apoptosis and improved barrier function in interleukin-10 gene-deficient mice. Immunol Res 2015;61:303-11. [PMID: 25588868 DOI: 10.1007/s12026-015-8625-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
245 Chen YJ, Mao R, Li XH, Cao QH, Chen ZH, Liu BX, Chen SL, Chen BL, He Y, Zeng ZR, Ben-Horin S, Rimola J, Rieder F, Xie XY, Chen MH. Real-Time Shear Wave Ultrasound Elastography Differentiates Fibrotic from Inflammatory Strictures in Patients with Crohn's Disease. Inflamm Bowel Dis 2018;24:2183-90. [PMID: 29718309 DOI: 10.1093/ibd/izy115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
246 Bo L, Fu H, Yang J. Comprehensive analysis of gene expression profiles provides insight into the pathogenesis of Crohn's disease. Mol Med Rep 2018;18:2643-50. [PMID: 30015893 DOI: 10.3892/mmr.2018.9267] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
247 Masselli G, Mastroiacovo I, De Marco E, Francione G, Casciani E, Polettini E, Gualdi G. Current tecniques and new perpectives research of magnetic resonance enterography in pediatric Crohn’s disease. World J Radiol 2016; 8(7): 668-682 [PMID: 27551337 DOI: 10.4329/wjr.v8.i7.668] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
248 Vasovic M, Gajovic N, Brajkovic D, Jovanovic M, Zdravkovaic N, Kanjevac T. The relationship between the immune system and oral manifestations of inflammatory bowel disease: a review. Cent Eur J Immunol. 2016;41:302-310. [PMID: 27833449 DOI: 10.5114/ceji.2016.63131] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
249 陈玮煦, 任丽华, 施瑞华. MiR-124在克罗恩病中的表达及其靶基因的确定. 世界华人消化杂志 2014; 22(11): 1622-1627 [DOI: 10.11569/wcjd.v22.i11.1622] [Reference Citation Analysis]
250 Yang Y, Lv X, Zhan L, Chen L, Jin H, Tang X, Shi Q, Zou Q, Xiang J, Zhang W, Zeng Z, Jiang H, Lv X. Case Report: IL-21 and Bcl-6 Regulate the Proliferation and Secretion of Tfh and Tfr Cells in the Intestinal Germinal Center of Patients With Inflammatory Bowel Disease. Front Pharmacol 2020;11:587445. [PMID: 33584264 DOI: 10.3389/fphar.2020.587445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
251 Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis 2019;25:270-82. [PMID: 30165490 DOI: 10.1093/ibd/izy269] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 27.0] [Reference Citation Analysis]
252 Fokam Tagne MA, Tchoffo A, Noubissi PA, Mazo AG, Kom B, Ngakou Mukam J, Sokeng Dongmo S, Kamgang R. Effects of hydro-ethanolic extract of leaves of Maesa lanceolata (Mursinaceae) on acetic acid-induced ulcerative colitis in rats. Inflammopharmacology 2021;29:1211-23. [PMID: 34101116 DOI: 10.1007/s10787-021-00825-8] [Reference Citation Analysis]
253 Guo Y, Zhou G, He C, Yang W, He Z, Liu Z. Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. Mediators Inflamm 2015;2015:843089. [PMID: 26106258 DOI: 10.1155/2015/843089] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
254 Ortiz-Masiá D, Cosín-Roger J, Calatayud S, Hernández C, Alós R, Hinojosa J, Apostolova N, Alvarez A, Barrachina MD. Hypoxic macrophages impair autophagy in epithelial cells through Wnt1: relevance in IBD. Mucosal Immunol 2014;7:929-38. [PMID: 24301659 DOI: 10.1038/mi.2013.108] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
255 Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018; 24(36): 4093-4103 [PMID: 30271076 DOI: 10.3748/wjg.v24.i36.4093] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
256 Roy S, Esmaeilniakooshkghazi A, Patnaik S, Wang Y, George SP, Ahrorov A, Hou JK, Herron AJ, Sesaki H, Khurana S. Villin-1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation. Gastroenterology 2018;154:1405-1420.e2. [PMID: 29274870 DOI: 10.1053/j.gastro.2017.12.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
257 Kono T, Fichera A. Surgical Treatment for Crohn's Disease: A Role of Kono-S Anastomosis in the West. Clin Colon Rectal Surg 2020;33:335-43. [PMID: 33162837 DOI: 10.1055/s-0040-1714236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
258 Li J, Doty A, Glover SC. Aryl hydrocarbon receptor signaling involves in the human intestinal ILC3/ILC1 conversion in the inflamed terminal ileum of Crohn's disease patients. Inflamm Cell Signal 2016;3:e1404. [PMID: 28286805 DOI: 10.14800/ics.1404] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
259 Boland BS, Sandborn WJ, Chang JT. Update on Janus kinase antagonists in inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43:603-617. [PMID: 25110261 DOI: 10.1016/j.gtc.2014.05.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
260 Ardesia M, Costantino G, Mondello P, Alibrandi A, Fries W. Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy. Gastroenterol Res Pract 2017;2017:4139656. [PMID: 29075289 DOI: 10.1155/2017/4139656] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
261 Mücke V, Mücke MM, Raine T, Bettenworth D. Diagnosis and treatment of anemia in patients with inflammatory bowel disease. Ann Gastroenterol 2017;30:15-22. [PMID: 28042234 DOI: 10.20524/aog.2016.0083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
262 Loddo I, Romano C. Inflammatory Bowel Disease: Genetics, Epigenetics, and Pathogenesis. Front Immunol. 2015;6:551. [PMID: 26579126 DOI: 10.3389/fimmu.2015.00551] [Cited by in Crossref: 166] [Cited by in F6Publishing: 142] [Article Influence: 27.7] [Reference Citation Analysis]
263 Kayama H, Tani H, Kitada S, Opasawatchai A, Okumura R, Motooka D, Nakamura S, Takeda K. BATF2 prevents T-cell-mediated intestinal inflammation through regulation of the IL-23/IL-17 pathway. Int Immunol 2019;31:371-83. [PMID: 30753547 DOI: 10.1093/intimm/dxz014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
264 Singhvi N, Gupta V, Gaur M, Sharma V, Puri A, Singh Y, Dubey GP, Lal R. Interplay of Human Gut Microbiome in Health and Wellness. Indian J Microbiol 2020;60:26-36. [PMID: 32089571 DOI: 10.1007/s12088-019-00825-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
265 Zhu Y, Xiang J, Liu W, Cao Q, Zhou W. Laparoscopy Combined with Enhanced Recovery Pathway in Ileocecal Resection for Crohn's Disease: A Randomized Study. Gastroenterol Res Pract 2018;2018:9648674. [PMID: 30534152 DOI: 10.1155/2018/9648674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
266 Ruiz MA, Junior RLK, Piron-Ruiz L, Saran PS, Castiglioni L, Quadros LG, Pinho TS, Burt RK. Medical, ethical, and legal aspects of hematopoietic stem cell transplantation for Crohn’s disease in Brazil. World J Stem Cells 2020; 12(10): 1113-1123 [PMID: 33178395 DOI: 10.4252/wjsc.v12.i10.1113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
267 Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20(12): 3255-3264 [PMID: 24695798 DOI: 10.3748/wjg.v20.i12.3255] [Cited by in CrossRef: 114] [Cited by in F6Publishing: 103] [Article Influence: 16.3] [Reference Citation Analysis]
268 Oberc A, Coombes BK. Convergence of External Crohn's Disease Risk Factors on Intestinal Bacteria. Front Immunol 2015;6:558. [PMID: 26579131 DOI: 10.3389/fimmu.2015.00558] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
269 Kameyama H, Nagahashi M, Shimada Y, Tajima Y, Ichikawa H, Nakano M, Sakata J, Kobayashi T, Narayanan S, Takabe K, Wakai T. Genomic characterization of colitis-associated colorectal cancer. World J Surg Oncol 2018;16:121. [PMID: 29966533 DOI: 10.1186/s12957-018-1428-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
270 Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY; GETAID CREOLE Study Group. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study. Gut 2018;67:53-60. [PMID: 28119352 DOI: 10.1136/gutjnl-2016-312581] [Cited by in Crossref: 102] [Cited by in F6Publishing: 94] [Article Influence: 25.5] [Reference Citation Analysis]
271 Ananthakrishnan AN, Cheng SC, Cai T, Cagan A, Gainer VS, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN. Serum inflammatory markers and risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1342-1348.e1. [PMID: 24407106 DOI: 10.1016/j.cgh.2013.12.030] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
272 Lo CH, Khalili H, Lochhead P, Song M, Lopes EW, Burke KE, Richter JM, Chan AT, Ananthakrishnan AN. Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. Aliment Pharmacol Ther 2021;53:598-607. [PMID: 33280139 DOI: 10.1111/apt.16210] [Reference Citation Analysis]
273 Lee HS, Jeong GS. 6,7,4'-Trihydroxyflavanone Protects against Dextran Sulfate Sodium-Induced Colitis by Regulating the Activity of T Cells and Colon Cells In Vivo. Int J Mol Sci 2021;22:2083. [PMID: 33669855 DOI: 10.3390/ijms22042083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Ortiz-Masiá D, Cosín-Roger J, Calatayud S, Hernández C, Alós R, Hinojosa J, Esplugues JV, Barrachina MD. M1 Macrophages Activate Notch Signalling in Epithelial Cells: Relevance in Crohn's Disease. J Crohns Colitis 2016;10:582-92. [PMID: 26802079 DOI: 10.1093/ecco-jcc/jjw009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
275 Srutkova D, Schwarzer M, Hudcovic T, Zakostelska Z, Drab V, Spanova A, Rittich B, Kozakova H, Schabussova I. Bifidobacterium longum CCM 7952 Promotes Epithelial Barrier Function and Prevents Acute DSS-Induced Colitis in Strictly Strain-Specific Manner. PLoS One. 2015;10:e0134050. [PMID: 26218526 DOI: 10.1371/journal.pone.0134050] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 14.7] [Reference Citation Analysis]
276 Schön MP. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol 2019;10:1764. [PMID: 31402919 DOI: 10.3389/fimmu.2019.01764] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
277 Bystrom J, Thomson SJ, Johansson J, Edin ML, Zeldin DC, Gilroy DW, Smith AM, Bishop-Bailey D. Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's disease? PLoS One. 2013;8:e75107. [PMID: 24058654 DOI: 10.1371/journal.pone.0075107] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
278 Derijks LJJ, Wong DR, Hommes DW, van Bodegraven AA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet 2018;57:1075-106. [PMID: 29512050 DOI: 10.1007/s40262-018-0639-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
279 Biancheri P, Foster MR, Fyfe MC, MacDonald TT, Sirohi S, Solanke Y, Wood E, Rowley A, Webber S, Walshe CA. Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1306-15. [PMID: 27104822 DOI: 10.1097/MIB.0000000000000759] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
280 Blander JM. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease. FEBS J. 2016;283:2720-2730. [PMID: 27250564 DOI: 10.1111/febs.13771] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 16.6] [Reference Citation Analysis]
281 Yamazaki H, So R, Matsuoka K, Kobayashi T, Shinzaki S, Matsuura M, Okabayashi S, Kataoka Y, Tsujimoto Y, Furukawa TA, Watanabe N. Certolizumab pegol for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2019;8:CD012893. [PMID: 31476018 DOI: 10.1002/14651858.CD012893.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Hampshire T, Menys A, Jaffer A, Bhatnagar G, Punwani S, Atkinson D, Halligan S, Hawkes DJ, Taylor SA. A Probabilistic Method for Estimation of Bowel Wall Thickness in MR Colonography. PLoS One 2017;12:e0168317. [PMID: 28072831 DOI: 10.1371/journal.pone.0168317] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
283 Soendergaard C, Kvist PH, Thygesen P, Reslow M, Nielsen OH, Kopchick JJ, Holm TL. Characterization of Growth Hormone Resistance in Experimental and Ulcerative Colitis. Int J Mol Sci. 2017;18:2046. [PMID: 28946616 DOI: 10.3390/ijms18102046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
284 Nashiry MA, Sumi SS, Sharif Shohan MU, Alyami SA, Azad AKM, Moni MA. Bioinformatics and system biology approaches to identify the diseasome and comorbidities complexities of SARS-CoV-2 infection with the digestive tract disorders. Brief Bioinform 2021:bbab126. [PMID: 33993223 DOI: 10.1093/bib/bbab126] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
285 Zwicker S, Lira-Junior R, Höög C, Almer S, Boström EA. Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study. Int J Mol Sci 2017;18:E1827. [PMID: 28829369 DOI: 10.3390/ijms18081827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
286 Lean QY, Eri RD, Fitton JH, Patel RP, Gueven N. Fucoidan Extracts Ameliorate Acute Colitis. PLoS One 2015;10:e0128453. [PMID: 26083103 DOI: 10.1371/journal.pone.0128453] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 7.5] [Reference Citation Analysis]
287 Avivar-Valderas A, Martín-Martín C, Ramírez C, Del Río B, Menta R, Mancheño-Corvo P, Ortiz-Virumbrales M, Herrero-Méndez Á, Panés J, García-Olmo D, Castañer JL, Palacios I, Lombardo E, Dalemans W, DelaRosa O. Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn's Disease Patients. Front Immunol 2019;10:1244. [PMID: 31258526 DOI: 10.3389/fimmu.2019.01244] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
288 Cai X, Shen W, Guo Z, Li Y, Cao L, Gong J, Zhu W. Thickness of Subcutaneous Fat Is a Predictive Factor of Incisional Surgical Site Infection in Crohn's Disease Surgery: A Retrospective Study. Gastroenterol Res Pract 2018;2018:1546075. [PMID: 30140279 DOI: 10.1155/2018/1546075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
289 Louis E, Ramos-Goñi JM, Cuervo J, Kopylov U, Barreiro-de Acosta M, McCartney S, Rosenfeld G, Bettenworth D, Hart A, Novak K, Donnet X, Easton D, Saldaña R, Protze K, Tzur E, Alperovich G, Casellas F. A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective. Patient 2020;13:317-25. [PMID: 31997116 DOI: 10.1007/s40271-019-00407-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
290 Timmermans WM, van Laar JA, van der Houwen TB, Kamphuis LS, Bartol SJ, Lam KH, Ouwendijk RJ, Sparrow MP, Gibson PR, van Hagen PM, van Zelm MC. B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy. PLoS One 2016;11:e0160103. [PMID: 27468085 DOI: 10.1371/journal.pone.0160103] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
291 Andersen V, Pedersen AK, Möller S, Green A. Chronic Inflammatory Diseases - Diabetes Mellitus, Rheumatoid Arthritis, Coeliac Disease, Crohn's Disease, and Ulcerative Colitis Among the Offspring of Affected Parents: A Danish Population-Based Registry Study. Clin Epidemiol 2021;13:13-20. [PMID: 33442298 DOI: 10.2147/CLEP.S286623] [Reference Citation Analysis]
292 Raad MA, Chams NH, Sharara AI. New and Evolving Immunotherapy in Inflammatory Bowel Disease. Inflamm Intest Dis. 2016;1:85-95. [PMID: 29922662 DOI: 10.1159/000445986] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
293 Rashid T, Ebringer A, Wilson C. The role of Klebsiella in Crohn's disease with a potential for the use of antimicrobial measures. Int J Rheumatol 2013;2013:610393. [PMID: 24223596 DOI: 10.1155/2013/610393] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
294 Robertson J, Haas CT, Pele LC, Monie TP, Charalambos C, Parkes M, Hewitt RE, Powell JJ. Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. Sci Rep 2016;6:26747. [PMID: 27226337 DOI: 10.1038/srep26747] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
295 Brenna Ø, Bruland T, Furnes MW, Granlund Av, Drozdov I, Emgård J, Brønstad G, Kidd M, Sandvik AK, Gustafsson BI. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. Scand J Gastroenterol 2015;50:1241-52. [PMID: 25979109 DOI: 10.3109/00365521.2015.1038849] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
296 Chen ML, Sundrud MS. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:1157-1167. [PMID: 26863267 DOI: 10.1097/mib.0000000000000714] [Cited by in Crossref: 57] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
297 Goyal N, Rana A, Ahlawat A, Bijjem KR, Kumar P. Animal models of inflammatory bowel disease: a review. Inflammopharmacology. 2014;22:219-233. [PMID: 24906689 DOI: 10.1007/s10787-014-0207-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 93] [Article Influence: 14.7] [Reference Citation Analysis]
298 Lopens S, Krawczyk M, Papp M, Milkiewicz P, Schierack P, Liu Y, Wunsch E, Conrad K, Roggenbuck D. The search for the Holy Grail: autoantigenic targets in primary sclerosing cholangitis associated with disease phenotype and neoplasia. Auto Immun Highlights 2020;11:6. [PMID: 32178720 DOI: 10.1186/s13317-020-00129-x] [Reference Citation Analysis]
299 Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:1295-1309. [PMID: 28569761 DOI: 10.1038/nprot.2017.044] [Cited by in Crossref: 333] [Cited by in F6Publishing: 338] [Article Influence: 83.3] [Reference Citation Analysis]
300 Narula N, Millson B, Charland K, Donepudi K, Gaetano T, McHugh K, Latour MG, Gazel S, Laliberté MC, Marshall JK. Impact of Adalimumab Patient Support Program's Care Coach Calls on Clinical Outcomes in Patients with Crohn's Disease in Canada: An Observational Retrospective Cohort Study. J Can Assoc Gastroenterol 2018;1:191-8. [PMID: 31294360 DOI: 10.1093/jcag/gwy059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
301 Cruz-Lebrón A, D'argenio Garcia L, Talla A, Joussef-Piña S, Quiñones-Mateu ME, Sékaly RP, de Carvalho KIL, Levine AD. Decreased Enteric Bacterial Composition and Diversity in South American Crohn's Disease Vary With the Choice of Treatment Strategy and Time Since Diagnosis. J Crohns Colitis 2020;14:791-800. [PMID: 31758685 DOI: 10.1093/ecco-jcc/jjz189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 Bettenworth D, Lopez R, Hindryckx P, Levesque BG, Rieder F. Heterogeneity in endoscopic treatment of Crohn’s disease-associated strictures: An international inflammatory bowel disease specialist survey. J Gastroenterol 2016;51:939-48. [DOI: 10.1007/s00535-016-1172-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
303 Levine AP, Pontikos N, Schiff ER, Jostins L, Speed D, Lovat LB, Barrett JC, Grasberger H, Plagnol V, Segal AW; NIDDK Inflammatory Bowel Disease Genetics Consortium. Genetic Complexity of Crohn's Disease in Two Large Ashkenazi Jewish Families. Gastroenterology 2016;151:698-709. [PMID: 27373512 DOI: 10.1053/j.gastro.2016.06.040] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 7.4] [Reference Citation Analysis]
304 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
305 Johannsen A, Fored MC, Håkansson J, Ekbom A, Gustafsson A. Consumption of dental treatment in patients with inflammatory bowel disease, a register study. PLoS One 2015;10:e0134001. [PMID: 26267797 DOI: 10.1371/journal.pone.0134001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
306 Pallotta N, Vincoli G, Pezzotti P, Giovannone M, Gigliozzi A, Badiali D, Vernia P, Corazziari ES. A risk score system to timely manage treatment in Crohn's disease: a cohort study. BMC Gastroenterol 2018;18:164. [PMID: 30400823 DOI: 10.1186/s12876-018-0889-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
307 Li J, Ueno A, Iacucci M, Fort Gasia M, Jijon HB, Panaccione R, Kaplan GG, Beck PL, Luider J, Barkema HW, Qian J, Gui X, Ghosh S. Crossover subsets of CD4+ T lymphocytes in the intestinal lamina propria of patients with Crohn's disease and ulcerative colitis. Dig Dis Sci. 2017;62:2357-2368. [PMID: 28573508 DOI: 10.1007/s10620-017-4596-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
308 Labarile N, Ghosh S, Ng SC, Walters J, Iacucci M. Tests that now deserve to be more widely adopted in IBD clinical practice. Therap Adv Gastroenterol 2020;13:1756284820944088. [PMID: 32782481 DOI: 10.1177/1756284820944088] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci 2016;61:3407-24. [PMID: 27655102 DOI: 10.1007/s10620-016-4317-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
310 Battat R, Dulai PS, Jairath V, Vande Casteele N. A product review of vedolizumab in inflammatory bowel disease. Hum Vaccin Immunother 2019;15:2482-90. [PMID: 30897022 DOI: 10.1080/21645515.2019.1591139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
311 Duan L, Huang H, Zhao X, Zhou M, Chen S, Wang C, Han Z, Han ZC, Guo Z, Li Z, Cao X. Extracellular vesicles derived from human placental mesenchymal stem cells alleviate experimental colitis in mice by inhibiting inflammation and oxidative stress. Int J Mol Med 2020;46:1551-61. [PMID: 32945344 DOI: 10.3892/ijmm.2020.4679] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
312 Maehata Y, Nagata Y, Moriyama T, Matsuno Y, Hirano A, Umeno J, Torisu T, Manabe T, Kitazono T, Esaki M. Risk of surgery in patients with stricturing type of Crohn's disease at the initial diagnosis: a single center experience. Intest Res 2019;17:357-64. [PMID: 30781932 DOI: 10.5217/ir.2018.00107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
313 Naser SA, Abdelsalam A, Thanigachalam S, Naser AS, Alcedo K. Domino effect of hypomagnesemia on the innate immunity of Crohn’s disease patients. World J Diabetes 2014; 5(4): 527-535 [PMID: 25126398 DOI: 10.4239/wjd.v5.i4.527] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
314 Lopes S, Andrade P, Afonso J, Cunha R, Rodrigues-Pinto E, Ramos I, Macedo G, Magro F. Monitoring Crohn's disease activity: endoscopy, fecal markers and computed tomography enterography. Therap Adv Gastroenterol 2018;11:1756284818769075. [PMID: 29760785 DOI: 10.1177/1756284818769075] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
315 Chi H, Wang D, Chen M, Lin J, Zhang S, Yu F, Zhou J, Zheng X, Zou Y. Shaoyao Decoction Inhibits Inflammation and Improves Intestinal Barrier Function in Mice With Dextran Sulfate Sodium-Induced Colitis. Front Pharmacol 2021;12:524287. [PMID: 33959000 DOI: 10.3389/fphar.2021.524287] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Ha F, Khalil H. Crohn's disease: a clinical update. Therap Adv Gastroenterol. 2015;8:352-359. [PMID: 26557891 DOI: 10.1177/1756283x15592585] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
317 Liu M, Lin X, Wang L, He Y, Chen M, Mao R. Thalidomide-induced sinus bradycardia in Crohn's disease: case report and literature review. J Int Med Res 2019;47:2228-33. [PMID: 30832535 DOI: 10.1177/0300060519833293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Kristensen MS, Kjærulff TM, Ersbøll AK, Green A, Hallas J, Thygesen LC. The Influence of Antidepressants on the Disease Course Among Patients With Crohn's Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study. Inflamm Bowel Dis 2019;25:886-93. [PMID: 30551218 DOI: 10.1093/ibd/izy367] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
319 Nguyen PM, Putoczki TL, Ernst M. STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease? J Interferon Cytokine Res. 2015;35:340-350. [PMID: 25760898 DOI: 10.1089/jir.2014.0225] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 9.0] [Reference Citation Analysis]
320 Kim YJ, Chang SY, Ko HJ. Myeloid-derived suppressor cells in inflammatory bowel disease. Intest Res 2015;13:105-11. [PMID: 25931994 DOI: 10.5217/ir.2015.13.2.105] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
321 Guo J, Jiang X, Gui S. RNA interference-based nanosystems for inflammatory bowel disease therapy. Int J Nanomedicine 2016;11:5287-310. [PMID: 27789943 DOI: 10.2147/IJN.S116902] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 5.2] [Reference Citation Analysis]
322 Baumgart DC, le Claire M. The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS One 2016;11:e0147364. [PMID: 26784027 DOI: 10.1371/journal.pone.0147364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
323 Ahmed SS, Dey N, Ashour AS, Sifaki-Pistolla D, Bălas-Timar D, Balas VE, Tavares JM. Effect of fuzzy partitioning in Crohn's disease classification: a neuro-fuzzy-based approach. Med Biol Eng Comput 2017;55:101-15. [PMID: 27106754 DOI: 10.1007/s11517-016-1508-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 13] [Article Influence: 11.4] [Reference Citation Analysis]
324 Zundler S, Neurath MF. Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer. Vaccines (Basel). 2016;4:5. [PMID: 26938566 DOI: 10.3390/vaccines4010005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 6.4] [Reference Citation Analysis]
325 Buttó LF, Schaubeck M, Haller D. Mechanisms of Microbe-Host Interaction in Crohn's Disease: Dysbiosis vs. Pathobiont Selection. Front Immunol 2015;6:555. [PMID: 26635787 DOI: 10.3389/fimmu.2015.00555] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
326 More S, Bøtner A, Butterworth A, Calistri P, Depner K, Edwards S, Garin-Bastuji B, Good M, Gortázar Schmidt C, Michel V, Miranda MA, Nielsen SS, Raj M, Sihvonen L, Spoolder H, Stegeman JA, Thulke HH, Velarde A, Willeberg P, Winckler C, Baldinelli F, Broglia A, Zancanaro G, Beltrán-Beck B, Kohnle L, Morgado J, Bicout D; EFSA Panel on Animal Health and Welfare (AHAW). Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): paratuberculosis. EFSA J 2017;15:e04960. [PMID: 32625604 DOI: 10.2903/j.efsa.2017.4960] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
327 Yu Y, Yin YH, Min L, Zhu ST, Li P, Zhang ST. Challenge in the new era: Translational medicine in gastrointestinal endoscopy and early cancer. Chronic Dis Transl Med 2019;5:234-42. [PMID: 32055782 DOI: 10.1016/j.cdtm.2019.12.002] [Reference Citation Analysis]
328 Sundblad V, Quintar AA, Morosi LG, Niveloni SI, Cabanne A, Smecuol E, Mauriño E, Mariño KV, Bai JC, Maldonado CA, Rabinovich GA. Galectins in Intestinal Inflammation: Galectin-1 Expression Delineates Response to Treatment in Celiac Disease Patients. Front Immunol 2018;9:379. [PMID: 29545799 DOI: 10.3389/fimmu.2018.00379] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
329 Esse S, Mason KJ, Green AC, Warren RB. Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. JAMA Dermatol 2020;156:787-94. [PMID: 32432649 DOI: 10.1001/jamadermatol.2020.1300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
330 Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A, Karlsson L. Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Eff Resour Alloc 2018;16:28. [PMID: 30123097 DOI: 10.1186/s12962-018-0114-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
331 2015 European Society of Coloproctology (ESCP) collaborating group. Patients with Crohn’s disease have longer post-operative in-hospital stay than patients with colon cancer but no difference in complications’ rate. World J Gastrointest Surg 2019; 11(5): 261-270 [PMID: 31171957 DOI: 10.4240/wjgs.v11.i5.261] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
332 Berkowitz L, Pardo-Roa C, Ramírez G, Vallejos OP, Sebastián VP, Riedel CA, Álvarez-Lobos M, Bueno SM. The absence of interleukin 10 affects the morphology, differentiation, granule content and the production of cryptidin-4 in Paneth cells in mice. PLoS One 2019;14:e0221618. [PMID: 31509557 DOI: 10.1371/journal.pone.0221618] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
333 Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV. A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohn's Disease. J Crohns Colitis 2018;12:1014-20. [PMID: 29846530 DOI: 10.1093/ecco-jcc/jjy070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
334 Hensel KO, Abellan Schneyder FE, Wilke L, Heusch A, Wirth S, Jenke AC. Speckle Tracking Stress Echocardiography Uncovers Early Subclinical Cardiac Involvement in Pediatric Patients with Inflammatory Bowel Diseases. Sci Rep 2017;7:2966. [PMID: 28592829 DOI: 10.1038/s41598-017-03255-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
335 Walldorf J, Hermann M, Porzner M, Pohl S, Metz H, Mäder K, Zipprich A, Christ B, Seufferlein T. In-vivo monitoring of acute DSS-Colitis using Colonoscopy, high resolution Ultrasound and bench-top Magnetic Resonance Imaging in Mice. Eur Radiol 2015;25:2984-91. [PMID: 25981216 DOI: 10.1007/s00330-015-3714-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
336 Dotimas J, Das M, Martin D. Cutaneous T-cell lymphoma in the setting of anti-tumor necrosis factor and immunomodulator therapy: A case report and literature review. SAGE Open Med Case Rep 2020;8:2050313X20937223. [PMID: 32655868 DOI: 10.1177/2050313X20937223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
337 Hu S, Png E, Gowans M, Ong DEH, de Sessions PF, Song J, Nagarajan N. Ectopic gut colonization: a metagenomic study of the oral and gut microbiome in Crohn's disease. Gut Pathog 2021;13:13. [PMID: 33632307 DOI: 10.1186/s13099-021-00409-5] [Reference Citation Analysis]
338 Wu MY, Liu L, Wang EJ, Xiao HT, Cai CZ, Wang J, Su H, Wang Y, Tan J, Zhang Z, Wang J, Yao M, Ouyang DF, Yue Z, Li M, Chen Y, Bian ZX, Lu JH. PI3KC3 complex subunit NRBF2 is required for apoptotic cell clearance to restrict intestinal inflammation. Autophagy 2021;17:1096-111. [PMID: 32160108 DOI: 10.1080/15548627.2020.1741332] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
339 Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine 2015;75:261-71. [PMID: 26113402 DOI: 10.1016/j.cyto.2015.05.030] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 14.8] [Reference Citation Analysis]
340 Ruiz MA, Kaiser Junior RL, Gouvêa Faria MA, de Quadros LG. Remission of refractory Crohn's disease after autologous hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter 2015;37:136-9. [PMID: 25818827 DOI: 10.1016/j.bjhh.2015.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
341 Honjo H, Watanabe T, Kamata K, Minaga K, Kudo M. RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:650403. [PMID: 33935757 DOI: 10.3389/fphar.2021.650403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Ruiz MA, Kaiser Junior RL, de Quadros LG, Caseiro GHX, Oliveira AF, Peña-Arciniegas T, Piron-Ruiz L, Kaiser FSL, Oliveira VL. Hematopoietic stem cell transplantation in a severe refractory Crohn's disease patient with intestinal stoma: a case report. Int Med Case Rep J 2017;10:353-9. [PMID: 29123428 DOI: 10.2147/IMCRJ.S139552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
343 Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc 2015;82:246-55. [PMID: 26005012 DOI: 10.1016/j.gie.2015.03.1974] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
344 Trivedi PJ, Bruns T, Ward S, Mai M, Schmidt C, Hirschfield GM, Weston CJ, Adams DH. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity. J Autoimmun 2016;68:98-104. [PMID: 26873648 DOI: 10.1016/j.jaut.2016.01.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 7.4] [Reference Citation Analysis]
345 Mao R, Tang RH, Qiu Y, Chen BL, Guo J, Zhang SH, Li XH, Feng R, He Y, Li ZP, Zeng ZR, Eliakim R, Ben-Horin S, Chen MH. Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? Therap Adv Gastroenterol. 2018;11:1756284818777938. [PMID: 29899757 DOI: 10.1177/1756284818777938] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
346 Bao S, Chiron S, Tang Y, Heiser CN, Southard-Smith AN, Lee HH, Ramirez MA, Huo Y, Washington MK, Scoville EA, Roland JT, Liu Q, Lau KS, Wilson KT, Coburn LA, Landman BA. A cross-platform informatics system for the Gut Cell Atlas: integrating clinical, anatomical and histological data. Proc SPIE Int Soc Opt Eng 2021;11601:1160106. [PMID: 34539029 DOI: 10.1117/12.2581074] [Reference Citation Analysis]
347 Pecoraro A, Nappi L, Crescenzi L, D'Armiento FP, Genovese A, Spadaro G. Chronic Diarrhea in Common Variable Immunodeficiency: a Case Series and Review of the Literature. J Clin Immunol. 2018;38:67-76. [PMID: 29138951 DOI: 10.1007/s10875-017-0461-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
348 Tielbeek JA, Ziech ML, Li Z, Lavini C, Bipat S, Bemelman WA, Roelofs JJ, Ponsioen CY, Vos FM, Stoker J. Evaluation of conventional, dynamic contrast enhanced and diffusion weighted MRI for quantitative Crohn's disease assessment with histopathology of surgical specimens. Eur Radiol. 2014;24:619-629. [PMID: 24037299 DOI: 10.1007/s00330-013-3015-7] [Cited by in Crossref: 134] [Cited by in F6Publishing: 124] [Article Influence: 16.8] [Reference Citation Analysis]
349 Bendix M, Dige A, Jørgensen SP, Dahlerup JF, Bibby BM, Deleuran B, Agnholt J. Seven Weeks of High-Dose Vitamin D Treatment Reduces the Need for Infliximab Dose-Escalation and Decreases Inflammatory Markers in Crohn's Disease during One-Year Follow-Up. Nutrients 2021;13:1083. [PMID: 33810258 DOI: 10.3390/nu13041083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Miot J, Smith S, Bhimsan N. Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective. Int J Clin Pharm 2016;38:880-7. [PMID: 27118462 DOI: 10.1007/s11096-016-0304-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
351 D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis 2018;12:188-96. [PMID: 28961770 DOI: 10.1093/ecco-jcc/jjx128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
352 Bobo TR, Fitzpatrick LR, Whitcomb TL, Cooper TK, Raiciulescu S, Smith JP. Role of the δ-Opioid Receptor in 2 Murine Models of Colitis. Comp Med 2020;70:25-34. [PMID: 31969211 DOI: 10.30802/AALAS-CM-19-000024] [Reference Citation Analysis]
353 Tawfik A, Flanagan PK, Campbell BJ. Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20(27): 8751-8763 [PMID: 25083050 DOI: 10.3748/wjg.v20.i27.8751] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
354 Yazısız V. Similarities and differences between Behçet's disease and Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(3): 228-238 [PMID: 25133025 DOI: 10.4291/wjgp.v5.i3.228] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
355 Ruder B, Atreya R, Becker C. Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases. Int J Mol Sci 2019;20:E1887. [PMID: 30995806 DOI: 10.3390/ijms20081887] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
356 Soendergaard C, Kvist PH, Seidelin JB, Pelzer H, Nielsen OH. Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes. J Gastroenterol 2016;51:796-807. [PMID: 26660730 DOI: 10.1007/s00535-015-1152-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
357 Földes A, Kádár K, Kerémi B, Zsembery Á, Gyires K, S Zádori Z, Varga G. Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Curr Neuropharmacol 2016;14:914-34. [PMID: 26791480 DOI: 10.2174/1570159x14666160121115210] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
358 Actis GC, Pellicano R, Rosina F. Inflammatory bowel disease: Traditional knowledge holds the seeds for the future. World J Gastrointest Pharmacol Ther 2015; 6(2): 10-16 [PMID: 25949845 DOI: 10.4292/wjgpt.v6.i2.10] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
359 Bai X, Bai G, Tang L, Liu L, Li Y, Jiang W. Changes in MMP-2, MMP-9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis. Exp Ther Med 2020;20:269-74. [PMID: 32536995 DOI: 10.3892/etm.2020.8710] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
360 McPhee JB, Small CL, Reid-Yu SA, Brannon JR, Le Moual H, Coombes BK. Host defense peptide resistance contributes to colonization and maximal intestinal pathology by Crohn's disease-associated adherent-invasive Escherichia coli. Infect Immun 2014;82:3383-93. [PMID: 24866805 DOI: 10.1128/IAI.01888-14] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 4.1] [Reference Citation Analysis]
361 Chen G, Yang Z, Wen D, Guo J, Xiong Q, Li P, Zhao L, Wang J, Wu C, Dong L. Polydatin has anti-inflammatory and antioxidant effects in LPS-induced macrophages and improves DSS-induced mice colitis. Immun Inflamm Dis 2021;9:959-70. [PMID: 34010516 DOI: 10.1002/iid3.455] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
362 Mahdi BM. Role of HLA typing on Crohn's disease pathogenesis. Ann Med Surg (Lond) 2015;4:248-53. [PMID: 26288728 DOI: 10.1016/j.amsu.2015.07.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
363 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
364 Zhang J, Wang XJ, Wu LJ, Yang L, Yang YT, Zhang D, Hong J, Li XY, Dong XQ, Guo XC, Han R, Ma X. Herb-partitioned moxibustion alleviates colonic inflammation in Crohn's disease rats by inhibiting hyperactivation of the NLRP3 inflammasome via regulation of the P2X7R-Pannexin-1 signaling pathway. PLoS One 2021;16:e0252334. [PMID: 34043726 DOI: 10.1371/journal.pone.0252334] [Reference Citation Analysis]
365 Abad C, Cheung-Lau G, Coûté-Monvoisin AC, Waschek JA. Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis. Neuroimmunomodulation 2015;22:203-12. [PMID: 25301381 DOI: 10.1159/000364912] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
366 Bianco C, Coluccio E, Prati D, Valenti L. Diagnosis and Management of Autoimmune Hemolytic Anemia in Patients with Liver and Bowel Disorders. J Clin Med 2021;10:423. [PMID: 33499290 DOI: 10.3390/jcm10030423] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Keshavarz Shahbaz S, Koushki K, Ayati SH, Bland AR, Bezsonov EE, Sahebkar A. Inflammasomes and Colorectal Cancer. Cells 2021;10:2172. [PMID: 34571825 DOI: 10.3390/cells10092172] [Reference Citation Analysis]
368 Marafini I, Stolfi C, Troncone E, Lolli E, Onali S, Paoluzi OA, Fantini MC, Biancone L, Calabrese E, Di Grazia A, Monteleone I, Lenti MV, Di Sabatino A, Monteleone G. A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study. BioDrugs 2021;35:325-36. [PMID: 33871807 DOI: 10.1007/s40259-021-00482-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Tamura S, Ishida N, Miyazu T, Onoue S, Tani S, Yamade M, Hamaya Y, Iwaizumi M, Osawa S, Furuta T, Sugimoto K. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation. Sci Rep 2020;10:21353. [PMID: 33288852 DOI: 10.1038/s41598-020-78603-9] [Reference Citation Analysis]
370 Aljebreen AM, Alharbi OR, Azzam NA, Almalki AS, Alswat KA, Almadi MA. Clinical epidemiology and phenotypic characteristics of Crohn's disease in the central region of Saudi Arabia. Saudi J Gastroenterol 2014;20:162-9. [PMID: 24976279 DOI: 10.4103/1319-3767.132993] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
371 Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG. Adalimumab for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2020;5:CD012877. [PMID: 32413933 DOI: 10.1002/14651858.CD012877.pub2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
373 Langbrandtner J, Hüppe A, Jessen P, Büning J, Nikolaus S, Raspe H, Bokemeyer B. Quality of care in inflammatory bowel disease: results of a prospective controlled cohort study in Germany (NETIBD). Clin Exp Gastroenterol 2017;10:215-27. [PMID: 28919797 DOI: 10.2147/CEG.S135346] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
374 Al-Saffar AK, Meijer CH, Gannavarapu VR, Hall G, Li Y, Diaz Tartera HO, Lördal M, Ljung T, Hellström PM, Webb DL. Parallel Changes in Harvey-Bradshaw Index, TNFα, and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease. Gastroenterol Res Pract 2017;2017:1745918. [PMID: 29201046 DOI: 10.1155/2017/1745918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
375 Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496 [PMID: 28293096 DOI: 10.3748/wjg.v23.i8.1489] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
376 Chen Y, Salem M, Boyd M, Bornholdt J, Li Y, Coskun M, Seidelin JB, Sandelin A, Nielsen OH. Relation between NOD2 genotype and changes in innate signaling in Crohn's disease on mRNA and miRNA levels. NPJ Genom Med 2017;2:3. [PMID: 29263823 DOI: 10.1038/s41525-016-0001-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
377 Tsuboi K, Nishitani M, Takakura A, Imai Y, Komatsu M, Kawashima H. Autophagy Protects against Colitis by the Maintenance of Normal Gut Microflora and Secretion of Mucus. J Biol Chem 2015;290:20511-26. [PMID: 26149685 DOI: 10.1074/jbc.M114.632257] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
378 Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging 2016;16:37. [PMID: 27149857 DOI: 10.1186/s12880-016-0139-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
379 Zarei-Kordshouli F, Geramizadeh B, Khodakaram-Tafti A. Prevalence of Mycobacterium avium subspecies paratuberculosis IS 900 DNA in biopsy tissues from patients with Crohn's disease: histopathological and molecular comparison with Johne's disease in Fars province of Iran. BMC Infect Dis 2019;19:23. [PMID: 30616527 DOI: 10.1186/s12879-018-3619-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
380 Berkowitz L, Pardo-Roa C, Salazar GA, Salazar-Echegarai F, Miranda JP, Ramírez G, Chávez JL, Kalergis AM, Bueno SM, Álvarez-Lobos M. Mucosal Exposure to Cigarette Components Induces Intestinal Inflammation and Alters Antimicrobial Response in Mice. Front Immunol 2019;10:2289. [PMID: 31608070 DOI: 10.3389/fimmu.2019.02289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
381 Valvano M, Magistroni M, Mancusi A, D'Ascenzo D, Longo S, Stefanelli G, Vernia F, Viscido A, Necozione S, Latella G. The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics. Nutrients 2021;13:323. [PMID: 33499406 DOI: 10.3390/nu13020323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Soontararak S, Chow L, Johnson V, Coy J, Webb C, Wennogle S, Dow S. Humoral immune responses against gut bacteria in dogs with inflammatory bowel disease. PLoS One 2019;14:e0220522. [PMID: 31369623 DOI: 10.1371/journal.pone.0220522] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
383 Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP. Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels. Gut Pathog 2020;12:1. [PMID: 31911822 DOI: 10.1186/s13099-019-0341-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 65.0] [Reference Citation Analysis]
384 De Vries LCS, Ghiboub M, van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D'Haens GR, Wildenberg ME, De Jonge WJ. Tyrosine Kinase 2 Signalling Drives Pathogenic T cells in Colitis. J Crohns Colitis 2021;15:617-30. [PMID: 33005945 DOI: 10.1093/ecco-jcc/jjaa199] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
385 Zhang W, Coba MP, Sun F. Inference of domain-disease associations from domain-protein, protein-disease and disease-disease relationships. BMC Syst Biol 2016;10 Suppl 1:4. [PMID: 26818594 DOI: 10.1186/s12918-015-0247-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
386 Schoultz M, Macaden L, Hubbard G. Participants' perspectives on mindfulness-based cognitive therapy for inflammatory bowel disease: a qualitative study nested within a pilot randomised controlled trial. Pilot Feasibility Stud 2016;2:3. [PMID: 27965824 DOI: 10.1186/s40814-015-0041-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
387 Feng JR, Qiu X, Wang F, Chen PF, Gao Q, Peng YN, Lin X, Liu Q, Liu J, Zhao Q, Li J. Diagnostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Crohn's Disease. Gastroenterol Res Pract 2017;2017:3526460. [PMID: 28798770 DOI: 10.1155/2017/3526460] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
388 Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut 2016;65:1642-64. [PMID: 26209553 DOI: 10.1136/gutjnl-2015-310022] [Cited by in Crossref: 80] [Cited by in F6Publishing: 83] [Article Influence: 13.3] [Reference Citation Analysis]
389 Nemati S, Teimourian S. An Overview of Inflammatory Bowel Disease: General Consideration and Genetic Screening Approach in Diagnosis of Early Onset Subsets. Middle East J Dig Dis. 2017;9:69-80. [PMID: 28638582 DOI: 10.15171/mejdd.2017.54] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
390 Nahum A, Filice G, Malhotra A. A Complicated Thread: Abdominal Actinomycosis in a Young Woman with Crohn Disease. Case Rep Gastroenterol 2017;11:377-81. [PMID: 28690491 DOI: 10.1159/000475917] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
391 Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine. 2018;30:317-325. [PMID: 29627390 DOI: 10.1016/j.ebiom.2018.03.030] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 32.7] [Reference Citation Analysis]
392 Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA. Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators. Front Immunol 2018;9:646. [PMID: 29670622 DOI: 10.3389/fimmu.2018.00646] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
393 El-Matary W, Deora V, Grover K. Barriers to clinical research in children with inflammatory bowel disease: The patients' perspective. PLoS One 2018;13:e0206965. [PMID: 30408097 DOI: 10.1371/journal.pone.0206965] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
394 Hufford MM, Kaplan MH. A gut reaction to IL-9. Nat Immunol. 2014;15:599-600. [PMID: 24940947 DOI: 10.1038/ni.2916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
395 Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project: dynamic analysis of microbiome-host omics profiles during periods of human health and disease. Cell Host Microbe. 2014;16:276-289. [PMID: 25211071 DOI: 10.1016/j.chom.2014.08.014] [Cited by in Crossref: 272] [Cited by in F6Publishing: 215] [Article Influence: 45.3] [Reference Citation Analysis]
396 Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol 2017;10:773-90. [PMID: 29051788 DOI: 10.1177/1756283X17727388] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
397 Zhu Y, Zhou W, Qi W, Liu W, Chen M, Zhu H, Xiang J, Xie Q, Chen P. Body mass index is a practical preoperative nutritional index for postoperative infectious complications after intestinal resection in patients with Crohn's disease.Medicine (Baltimore). 2017;96:e7113. [PMID: 28591060 DOI: 10.1097/MD.0000000000007113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
398 Ateş Bulut E, Törüner M. The influence of disease type and activity to sexual life and health quality in inflammatory bowel disease. Turk J Gastroenterol 2019;30:33-9. [PMID: 30644362 DOI: 10.5152/tjg.2018.18250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Yamada A, Arakaki R, Saito M, Tsunematsu T, Kudo Y, Ishimaru N. Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2016; 22(7): 2195-2205 [PMID: 26900284 DOI: 10.3748/wjg.v22.i7.2195] [Cited by in CrossRef: 84] [Cited by in F6Publishing: 79] [Article Influence: 16.8] [Reference Citation Analysis]
400 Randall CW, Vizuete JA, Martinez N, Alvarez JJ, Garapati KV, Malakouti M, Taboada CM. From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol 2015;8:143-59. [PMID: 25949527 DOI: 10.1177/1756283X15576462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
401 Chan HC, Ng SC. Emerging biologics in inflammatory bowel disease. J Gastroenterol. 2017;52:141-150. [PMID: 27832357 DOI: 10.1007/s00535-016-1283-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
402 林艳, 郑长青. 炎症性肠病与间充质干细胞的研究进展. 世界华人消化杂志 2014; 22(4): 521-526 [DOI: 10.11569/wcjd.v22.i4.521] [Reference Citation Analysis]
403 Wu P, Jia F, Zhang B, Zhang P. Risk of cardiovascular disease in inflammatory bowel disease. Exp Ther Med 2017;13:395-400. [PMID: 28352306 DOI: 10.3892/etm.2016.3966] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 7.2] [Reference Citation Analysis]
404 Ruiz MA, Kaiser Junior RL, Piron-Ruiz L, Peña-Arciniegas T, Saran PS, De Quadros LG. Hematopoietic stem cell transplantation for Crohn’s disease: Gaps, doubts and perspectives. World J Stem Cells 2018; 10(10): 134-137 [PMID: 30397423 DOI: 10.4252/wjsc.v10.i10.134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
405 Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155-G162. [PMID: 26608188 DOI: 10.1152/ajpgi.00311.2015] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 14.3] [Reference Citation Analysis]
406 Legaki E, Gazouli M. Influence of environmental factors in the development of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther 2016; 7(1): 112-125 [PMID: 26855817 DOI: 10.4292/wjgpt.v7.i1.112] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
407 Sohn B, Kim MJ, Koh H, Han KH, Lee MJ. Intestinal lesions in pediatric Crohn disease: comparative detectability among pulse sequences at MR enterography. Pediatr Radiol 2014;44:821-30. [PMID: 24584271 DOI: 10.1007/s00247-014-2902-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
408 Martinez-Medina M, Strozzi F, Castillo BRD, Serrano-Morillas N, Bustins NF, Martínez-Martínez L. Antimicrobial Resistance Profiles of Adherent Invasive Escherichia coli Show Increased Resistance to β-Lactams. Antibiotics (Basel) 2020;9:E251. [PMID: 32414140 DOI: 10.3390/antibiotics9050251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
409 Li H, Shi FH, Huang SY, Zhang SG, Gu ZC, Wei JF. Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails. Medicine (Baltimore) 2018;97:e11507. [PMID: 29995817 DOI: 10.1097/MD.0000000000011507] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
410 Liu TC, Naito T, Liu Z, VanDussen KL, Haritunians T, Li D, Endo K, Kawai Y, Nagasaki M, Kinouchi Y, McGovern DP, Shimosegawa T, Kakuta Y, Stappenbeck TS. LRRK2 but not ATG16L1 is associated with Paneth cell defect in Japanese Crohn's disease patients. JCI Insight 2017;2:e91917. [PMID: 28352666 DOI: 10.1172/jci.insight.91917] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
411 Steinmann S, Scheibe K, Erlenbach-Wuensch K, Neufert C, Schneider-Stock R. Death-associated protein kinase: A molecule with functional antagonistic duality and a potential role in inflammatory bowel disease (Review). Int J Oncol 2015;47:5-15. [PMID: 25963636 DOI: 10.3892/ijo.2015.2998] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
412 Xue G, Hua L, Zhou N, Li J. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis. Bioengineered 2021;12:252-65. [PMID: 33323040 DOI: 10.1080/21655979.2020.1863016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
413 Słowińska-Solnica K, Pawlica-Gosiewska D, Gawlik K, Owczarek D, Cibor D, Pocztar H, Mach T, Solnica B. Serum inflammatory markers in the diagnosis and assessment of Crohn's disease activity. Arch Med Sci 2021;17:252-7. [PMID: 33488879 DOI: 10.5114/aoms/130842] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
414 Pagnini C, Pizarro TT, Cominelli F. Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor. Front Pharmacol. 2019;10:671. [PMID: 31316377 DOI: 10.3389/fphar.2019.00671] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 16.0] [Reference Citation Analysis]
415 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
416 Wang S, Dai Y, Zhang J, Ou D, Ouyang C, Lu F. Intestinal ulcers as an initial finding in EBV-associated lymphoproliferative disorder: A case report. Medicine (Baltimore) 2020;99:e18764. [PMID: 32011464 DOI: 10.1097/MD.0000000000018764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
417 Pisani LF, Moriggi M, Gelfi C, Vecchi M, Pastorelli L. Proteomic insights on the metabolism in inflammatory bowel disease. World J Gastroenterol 2020; 26(7): 696-705 [PMID: 32116417 DOI: 10.3748/wjg.v26.i7.696] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
418 Chiu B, Chan J, Das S, Alshamma Z, Sergi C. Pediatric Sarcoidosis: A Review with Emphasis on Early Onset and High-Risk Sarcoidosis and Diagnostic Challenges. Diagnostics (Basel) 2019;9:E160. [PMID: 31731423 DOI: 10.3390/diagnostics9040160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
419 Zhang M, Merlin D. Nanoparticle-Based Oral Drug Delivery Systems Targeting the Colon for Treatment of Ulcerative Colitis. Inflamm Bowel Dis 2018;24:1401-15. [PMID: 29788186 DOI: 10.1093/ibd/izy123] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 20.0] [Reference Citation Analysis]
420 Bosca-Watts MM, Minguez M, Planelles D, Navarro S, Rodriguez A, Santiago J, Tosca J, Mora F. HLA-DQ: Celiac disease vs inflammatory bowel disease. World J Gastroenterol 2018; 24(1): 96-103 [PMID: 29358886 DOI: 10.3748/wjg.v24.i1.96] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
421 Aryan A, Azizi Z, Teimouri A, Ebrahimi Daryani N, Aletaha N, Jahanbakhsh A, Nouritaromlou MK, Alborzi F, Mami M, Basirat V, Javid Anbardan S. The Diagnostic Role of Magnetic Resonance Enterography as a Complementary Test to Colonoscopy in Active Crohn's Disease. Middle East J Dig Dis 2016;8:93-101. [PMID: 27252815 DOI: 10.15171/mejdd.2016.13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
422 Niu YW, Qu CQ, Wang GH, Yan GY. RWHMDA: Random Walk on Hypergraph for Microbe-Disease Association Prediction. Front Microbiol 2019;10:1578. [PMID: 31354672 DOI: 10.3389/fmicb.2019.01578] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
423 Xu S, Xu ZX, Yan S, Le J, Chen H, Ming L, Xu SG, Lin T. Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets. Exp Ther Med 2019;18:1099-106. [PMID: 31316605 DOI: 10.3892/etm.2019.7662] [Reference Citation Analysis]
424 Wang L, Yu Z, Wan S, Wu F, Chen W, Zhang B, Lin D, Liu J, Xie H, Sun X, Wu Z. Exosomes Derived from Dendritic Cells Treated with Schistosoma japonicum Soluble Egg Antigen Attenuate DSS-Induced Colitis. Front Pharmacol 2017;8:651. [PMID: 28959207 DOI: 10.3389/fphar.2017.00651] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
425 Cooper J, Blake I, Lindsay JO, Hawkey CJ. Living with Crohn's disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study). BMJ Open 2017;7:e015201. [PMID: 28893742 DOI: 10.1136/bmjopen-2016-015201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
426 Malesza IJ, Malesza M, Krela-Kaźmierczak I, Zielińska A, Souto EB, Dobrowolska A, Eder P. Primary Humoral Immune Deficiencies: Overlooked Mimickers of Chronic Immune-Mediated Gastrointestinal Diseases in Adults. Int J Mol Sci 2020;21:E5223. [PMID: 32718006 DOI: 10.3390/ijms21155223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
427 Lira-Junior R, Figueredo CM. Periodontal and inflammatory bowel diseases: Is there evidence of complex pathogenic interactions? World J Gastroenterol 2016; 22(35): 7963-7972 [PMID: 27672291 DOI: 10.3748/wjg.v22.i35.7963] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
428 Gao SJ, Zhang L, Lu W, Wang L, Chen L, Zhu Z, Zhu HH. Interleukin-18 genetic polymorphisms contribute differentially to the susceptibility to Crohn’s disease. World J Gastroenterol 2015; 21(28): 8711-8722 [PMID: 26229413 DOI: 10.3748/wjg.v21.i28.8711] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
429 Chen M, Zhu H, Mao YJ, Cao N, Yu YL, Li LY, Zhao Q, Wu M, Ye M. Regulation of IL12B Expression in Human Macrophages by TALEN-mediated Epigenome Editing. Curr Med Sci 2020;40:900-9. [PMID: 33123904 DOI: 10.1007/s11596-020-2249-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
430 Bakhshi Z, Yadav S, Salonen BR, Bonnes SL, Varayil JE, Harmsen WS, Hurt RT, Tremaine WJ, Loftus EV Jr. Incidence and Outcomes of Home Parenteral Nutrition in Patients With Crohn Disease in Olmsted County, Minnesota. Crohns Colitis 360 2020;2:otaa083. [PMID: 34142084 DOI: 10.1093/crocol/otaa083] [Reference Citation Analysis]
431 Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: A review. World J Gastroenterol 2013; 19(43): 7652-7660 [PMID: 24282355 DOI: 10.3748/wjg.v19.i43.7652] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
432 Deepak P, Park SH, Ehman EC, Hansel SL, Fidler JL, Bruining DH, Fletcher JG. Crohn’s disease diagnosis, treatment approach, and management paradigm: what the radiologist needs to know. Abdom Radiol 2017;42:1068-86. [DOI: 10.1007/s00261-017-1068-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
433 Ruiz MA, Kaiser RL Jr, de Quadros LG, Piron-Ruiz L, Peña-Arciniegas T, Faria MAG, Siqueira RC, Pirozzi FF, Kaiser FSL, Burt RK. Low toxicity and favorable clinical and quality of life impact after non-myeloablative autologous hematopoietic stem cell transplant in Crohn's disease. BMC Res Notes 2017;10:495. [PMID: 28985769 DOI: 10.1186/s13104-017-2824-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
434 Ananthakrishnan AN, Luo C, Yajnik V, Khalili H, Garber JJ, Stevens BW, Cleland T, Xavier RJ. Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host Microbe 2017; 21: 603-610. e3. [PMID: 28494241 DOI: 10.1016/j.chom.2017.04.010] [Cited by in Crossref: 150] [Cited by in F6Publishing: 135] [Article Influence: 37.5] [Reference Citation Analysis]
435 Chen ML, Sundrud MS. Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22:1157-1167. [PMID: 26863267 DOI: 10.1097/mib.000000 0000000714] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn's disease and ulcerative colitis. A systematic review. Arch Med Sci 2016;12:295-302. [PMID: 27186172 DOI: 10.5114/aoms.2016.59254] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
437 Choi M, Lim S, Choi MG, Shim KN, Lee SH. Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn's Disease: A Meta-Analysis. Gut Liver 2017;11:62-72. [PMID: 27728963 DOI: 10.5009/gnl16015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
438 Chandan JS, Thomas T. The impact of inflammatory bowel disease on oral health. Br Dent J 2017;222:549-53. [PMID: 28387295 DOI: 10.1038/sj.bdj.2017.318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
439 Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:998-1009. [PMID: 26835982 DOI: 10.1097/MIB.0000000000000661] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
440 Al-Kofahi M, Becker F, Gavins FN, Woolard MD, Tsunoda I, Wang Y, Ostanin D, Zawieja DC, Muthuchamy M, von der Weid PY. IL-1β reduces tonic contraction of mesenteric lymphatic muscle cells, with the involvement of cycloxygenase-2 and prostaglandin E2. Br J Pharmacol. 2015;172:4038-4051. [PMID: 25989136 DOI: 10.1111/bph.13194] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
441 Haring E, Zeiser R, Apostolova P. Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. Front Immunol 2021;12:705342. [PMID: 34249014 DOI: 10.3389/fimmu.2021.705342] [Reference Citation Analysis]
442 Sankarasubramanian J, Ahmad R, Avuthu N, Singh AB, Guda C. Gut Microbiota and Metabolic Specificity in Ulcerative Colitis and Crohn's Disease. Front Med (Lausanne) 2020;7:606298. [PMID: 33330572 DOI: 10.3389/fmed.2020.606298] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
443 Dong J, Wang H, Zhao J, Zhu W, Zhang L, Gong J, Li Y, Gu L, Li J. Ultrasound as a diagnostic tool in detecting active Crohn's disease: a meta-analysis of prospective studies. Eur Radiol. 2014;24:26-33. [PMID: 23921767 DOI: 10.1007/s00330-013-2973-0] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
444 Feldbrügge L, Moss AC, Yee EU, Csizmadia E, Mitsuhashi S, Longhi MS, Sandhu B, Stephan H, Wu Y, Cheifetz AS, Müller CE, Sévigny J, Robson SC, Jiang ZG. Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. J Crohns Colitis 2017;11:1113-23. [PMID: 28472257 DOI: 10.1093/ecco-jcc/jjx058] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
445 Huang C, Shi G. Smoking and microbiome in oral, airway, gut and some systemic diseases. J Transl Med. 2019;17:225. [PMID: 31307469 DOI: 10.1186/s12967-019-1971-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 26.0] [Reference Citation Analysis]
446 Kotze PG, Saab MP, Saab B, da Silva Kotze LM, Olandoski M, Pinheiro LV, Martinez CA, Ayrizono ML, Magro DO, Coy CS. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. Dig Dis Sci 2017;62:456-64. [PMID: 27933472 DOI: 10.1007/s10620-016-4400-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
447 Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049-59. [PMID: 28209624 DOI: 10.1136/gutjnl-2016-312735] [Cited by in Crossref: 167] [Cited by in F6Publishing: 153] [Article Influence: 41.8] [Reference Citation Analysis]
448 VanDussen KL, Liu TC, Li D, Towfic F, Modiano N, Winter R, Haritunians T, Taylor KD, Dhall D, Targan SR. Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn’s disease. Gastroenterology. 2014;146:200-209. [PMID: 24076061 DOI: 10.1053/j.gastro.2013.09.048] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 13.8] [Reference Citation Analysis]
449 Zwicker S, Bureik D, Bosma M, Martinez GL, Almer S, Boström EA. Receptor-Type Protein-Tyrosine Phosphatase ζ and Colony Stimulating Factor-1 Receptor in the Intestine: Cellular Expression and Cytokine- and Chemokine Responses by Interleukin-34 and Colony Stimulating Factor-1. PLoS One 2016;11:e0167324. [PMID: 27898738 DOI: 10.1371/journal.pone.0167324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
450 Vich Vila A, Collij V, Sanna S, Sinha T, Imhann F, Bourgonje AR, Mujagic Z, Jonkers DMAE, Masclee AAM, Fu J, Kurilshikov A, Wijmenga C, Zhernakova A, Weersma RK. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nat Commun. 2020;11:362. [PMID: 31953381 DOI: 10.1038/s41467-019-14177-z] [Cited by in Crossref: 103] [Cited by in F6Publishing: 106] [Article Influence: 103.0] [Reference Citation Analysis]
451 Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019;10:279. [PMID: 30983996 DOI: 10.3389/fphar.2019.00279] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 22.0] [Reference Citation Analysis]
452 Papanikolaou I, Kagouridis K, Papiris SA. Patterns of airway involvement in inflammatory bowel diseases. World J Gastrointest Pathophysiol 2014; 5(4): 560-569 [PMID: 25400999 DOI: 10.4291/wjgp.v5.i4.560] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
453 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
454 Pagnini C, Siakavellas SI, Bamias G. Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. Gastroenterol Res Pract 2018;2018:6317057. [PMID: 30116266 DOI: 10.1155/2018/6317057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
455 Kotze PG, Spinelli A, da Silva RN, de Barcelos IF, Teixeira FV, Saad-Hossne R, de Albuquerque IC, Olandoski M, da Silva Kotze LM, Suzuki Y. Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study. Intest Res. 2015;13:259-265. [PMID: 26131001 DOI: 10.5217/ir.2015.13.3.259] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
456 Decara J, Rivera P, López-Gambero AJ, Serrano A, Pavón FJ, Baixeras E, Rodríguez de Fonseca F, Suárez J. Peroxisome Proliferator-Activated Receptors: Experimental Targeting for the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:730. [PMID: 32536865 DOI: 10.3389/fphar.2020.00730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
457 Guo D, Yang J, Ling F, Tu L, Li J, Chen Y, Zou K, Zhu L, Hou X. Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis. J Immunol Res 2020;2020:9430763. [PMID: 32855978 DOI: 10.1155/2020/9430763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Mahlich J, Matsuoka K, Nakamura Y, Sruamsiri R. The relationship between socio-demographic factors, health status, treatment type, and employment outcome in patients with inflammatory bowel disease in Japan. BMC Public Health 2017;17:623. [PMID: 28676039 DOI: 10.1186/s12889-017-4516-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
459 Zhu C, Song K, Shen Z, Quan Y, Tan B, Luo W, Wu S, Tang K, Yang Z, Wang X. Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis. Mol Med Rep 2018;17:7567-74. [PMID: 29620246 DOI: 10.3892/mmr.2018.8833] [Cited by in Crossref: 10] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
460 Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, Fedyk E, Fox I. A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab. Clin Pharmacokinet 2017;56:1287-301. [PMID: 28523450 DOI: 10.1007/s40262-017-0546-0] [Cited by in Crossref: 74] [Cited by in F6Publishing: 68] [Article Influence: 24.7] [Reference Citation Analysis]
461 Liebert A, Wileńska A, Czuber-Dochan W, Kłopocka M. Translation and validation of the inflammatory bowel disease fatigue (IBD-F) patient self-assessment questionnaire. Prz Gastroenterol 2021;6:136-43. [PMID: 34276841 DOI: 10.5114/pg.2021.106665] [Reference Citation Analysis]
462 M’Koma AE. Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics. World J Gastrointest Surg. 2014;6:208-219. [PMID: 25429322 DOI: 10.4240/wjgs.v6.i11.20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
463 Kvivik I, Grimstad T, Jonsson G, Kvaløy JT, Omdal R. Anti-HMGB1 auto-Abs influence fatigue in patients with Crohn's disease. Innate Immun 2021;27:286-93. [PMID: 33940970 DOI: 10.1177/17534259211014252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
464 Hughes ER, Winter MG, Duerkop BA, Spiga L, Furtado de Carvalho T, Zhu W, Gillis CC, Büttner L, Smoot MP, Behrendt CL, Cherry S, Santos RL, Hooper LV, Winter SE. Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis. Cell Host Microbe 2017;21:208-19. [PMID: 28182951 DOI: 10.1016/j.chom.2017.01.005] [Cited by in Crossref: 127] [Cited by in F6Publishing: 115] [Article Influence: 31.8] [Reference Citation Analysis]
465 Parente JML, Coy CSR, Campelo V, Parente MPPD, Costa LA, Silva RMD, Stephan C, Zeitune JMR. Inflammatory bowel disease in an underdeveloped region of Northeastern Brazil. World J Gastroenterol 2015; 21(4): 1197-1206 [PMID: 25632193 DOI: 10.3748/wjg.v21.i4.1197] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
466 Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018;14:2597-611. [PMID: 29624476 DOI: 10.1080/21645515.2018.1461297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
467 Simčič S, Berlec A, Stopinšek S, Štrukelj B, Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient's mucosa. World J Microbiol Biotechnol 2019;35:45. [PMID: 30810891 DOI: 10.1007/s11274-019-2615-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
468 Villumsen M, Schelde AB, Jimenez-Solem E, Jess T, Allin KH. GLP-1 based therapies and disease course of inflammatory bowel disease. EClinicalMedicine 2021;37:100979. [PMID: 34386751 DOI: 10.1016/j.eclinm.2021.100979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
469 Hanson ED, Bates LC, Bartlett DB, Campbell JP. Does exercise attenuate age- and disease-associated dysfunction in unconventional T cells? Shining a light on overlooked cells in exercise immunology. Eur J Appl Physiol 2021;121:1815-34. [PMID: 33822261 DOI: 10.1007/s00421-021-04679-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
470 Coppell KJ, Galts CP, Huizing FY, Norton JK, Gray AR, Schultz K, Hobbs CE, Aluzaite K, Schultz M. Annual Incidence and Phenotypic Presentation of IBD in Southern New Zealand: An 18-Year Epidemiological Analysis. Inflamm Intest Dis 2018;3:32-9. [PMID: 30505840 DOI: 10.1159/000492615] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
471 Yoon K, Chang KT, Lee HJ. MRI for Crohn’s Disease: Present and Future. Biomed Res Int. 2015;2015:786802. [PMID: 26413543 DOI: 10.1155/2015/786802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
472 Kavanagh RG, O'Grady J, Carey BW, McLaughlin PD, O'Neill SB, Maher MM, O'Connor OJ. Low-Dose Computed Tomography for the Optimization of Radiation Dose Exposure in Patients with Crohn's Disease. Gastroenterol Res Pract 2018;2018:1768716. [PMID: 30515203 DOI: 10.1155/2018/1768716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int J Mol Sci. 2019;20. [PMID: 31295952 DOI: 10.3390/ijms20143394] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 37.0] [Reference Citation Analysis]
474 Weigmann B, Neurath MF. Th9 cells in inflammatory bowel diseases. Semin Immunopathol. 2017;39:89-95. [PMID: 27837255 DOI: 10.1007/s00281-016-0603-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
475 Kim MS, Kim JY. Ginger attenuates inflammation in a mouse model of dextran sulfate sodium-induced colitis. Food Sci Biotechnol 2018;27:1493-501. [PMID: 30319860 DOI: 10.1007/s10068-018-0438-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
476 Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int J Mol Sci. 2017;18. [PMID: 28617319 DOI: 10.3390/ijms18061276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
477 Artom M, Czuber-Dochan W, Sturt J, Proudfoot H, Roberts D, Norton C. Cognitive-behavioural therapy for the management of inflammatory bowel disease-fatigue: a feasibility randomised controlled trial. Pilot Feasibility Stud 2019;5:145. [PMID: 31890258 DOI: 10.1186/s40814-019-0538-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
478 Tan G, Li RH, Li C, Wu F, Zhao XM, Ma JY, Lei S, Zhang WD, Zhi FC. Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the paneth cell lineage. Sci Rep 2015;5:8383. [PMID: 25670499 DOI: 10.1038/srep08383] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
479 Watanabe Y, Mizushima T, Okumura R, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Matsuda C, Yamamoto H, Takeda K, Doki Y, Eguchi H. Fecal Stream Diversion Changes Intestinal Environment, Modulates Mucosal Barrier, and Attenuates Inflammatory Cells in Crohn's Disease. Dig Dis Sci 2021. [PMID: 34041649 DOI: 10.1007/s10620-021-07060-9] [Reference Citation Analysis]
480 Kong Z, He M, Luo Q, Huang X, Wei P, Cheng Y, Chen L, Liang Y, Lu Y, Li X, Chen J. Multi-Task Classification and Segmentation for Explicable Capsule Endoscopy Diagnostics. Front Mol Biosci 2021;8:614277. [PMID: 34490342 DOI: 10.3389/fmolb.2021.614277] [Reference Citation Analysis]
481 Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329-342. [PMID: 24751956 DOI: 10.1038/nri3661] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 1090] [Article Influence: 161.3] [Reference Citation Analysis]
482 Buttó LF, Pelletier A, More SK, Zhao N, Osme A, Hager CL, Ghannoum MA, Sekaly RP, Cominelli F, Dave M. Intestinal Stem Cell Niche Defects Result in Impaired 3D Organoid Formation in Mouse Models of Crohn's Disease-like Ileitis. Stem Cell Reports 2020;15:389-407. [PMID: 32679063 DOI: 10.1016/j.stemcr.2020.06.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
483 Li J, Doty AL, Tang Y, Berrie D, Iqbal A, Tan SA, Clare-Salzler MJ, Wallet SM, Glover SC. Enrichment of IL-17A+ IFN-γ+ and IL-22+ IFN-γ+ T cell subsets is associated with reduction of NKp44+ ILC3s in the terminal ileum of Crohn's disease patients. Clin Exp Immunol 2017;190:143-53. [PMID: 28586085 DOI: 10.1111/cei.12996] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
484 Alvarez-Lobos M, Pizarro DP, Palavecino CE, Espinoza A, Sebastián VP, Alvarado JC, Ibañez P, Quintana C, Díaz O, Kalergis AM, Bueno SM. Role of Salmonella enterica exposure in Chilean Crohn's disease patients. World J Gastroenterol 2013; 19(35): 5855-5862 [PMID: 24124330 DOI: 10.3748/wjg.v19.i35.5855] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
485 Yu Q, Mao R, Lian L, Ng SC, Zhang S, Chen Z, Zhang Y, Qiu Y, Chen B, He Y, Zeng Z, Ben-Horin S, Song X, Chen M. Surgical management of inflammatory bowel disease in China: a systematic review of two decades. Intest Res 2016;14:322-32. [PMID: 27799883 DOI: 10.5217/ir.2016.14.4.322] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
486 Babic M, Romagnani C. The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Front Immunol 2018;9:1219. [PMID: 29910814 DOI: 10.3389/fimmu.2018.01219] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
487 Schäffler H, Rohde M, Rohde S, Huth A, Gittel N, Hollborn H, Koczan D, Glass Ä, Lamprecht G, Jaster R. NOD2- and disease-specific gene expression profiles of peripheral blood mononuclear cells from Crohn’s disease patients. World J Gastroenterol 2018; 24(11): 1196-1205 [PMID: 29568200 DOI: 10.3748/wjg.v24.i11.1196] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
488 Berkowitz L, Schultz BM, Salazar GA, Pardo-Roa C, Sebastián VP, Álvarez-Lobos MM, Bueno SM. Impact of Cigarette Smoking on the Gastrointestinal Tract Inflammation: Opposing Effects in Crohn's Disease and Ulcerative Colitis. Front Immunol 2018;9:74. [PMID: 29441064 DOI: 10.3389/fimmu.2018.00074] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 19.3] [Reference Citation Analysis]
489 Kilcoyne A, Kaplan JL, Gee MS. Inflammatory bowel disease imaging: Current practice and future directions. World J Gastroenterol 2016; 22(3): 917-932 [PMID: 26811637 DOI: 10.3748/wjg.v22.i3.917] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 38] [Article Influence: 10.6] [Reference Citation Analysis]
490 Lo CH, Lochhead P, Khalili H, Song M, Tabung FK, Burke KE, Richter JM, Giovannucci EL, Chan AT, Ananthakrishnan AN. Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology 2020;159:873-883.e1. [PMID: 32389666 DOI: 10.1053/j.gastro.2020.05.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
491 Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open 2015;1:e000097. [PMID: 26509073 DOI: 10.1136/rmdopen-2015-000097] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 11.2] [Reference Citation Analysis]
492 Manuc TE, Manuc MM, Diculescu MM. Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. Clin Exp Gastroenterol 2016;9:59-70. [PMID: 27042137 DOI: 10.2147/CEG.S53381] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
493 Gollifer RM, Menys A, Makanyanga J, Puylaert CA, Vos FM, Stoker J, Atkinson D, Taylor SA. Relationship between MRI quantified small bowel motility and abdominal symptoms in Crohn's disease patients-a validation study. Br J Radiol 2018;91:20170914. [PMID: 29888980 DOI: 10.1259/bjr.20170914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
494 Matuszyk A, Ceranowicz P, Warzecha Z, Cieszkowski J, Gałązka K, Bonior J, Jaworek J, Konturek PC, Gil K, Dembiński A. Pretreatment with obestatin inhibits the development of acetic acid-induced colitis in rats. Arch Med Sci 2018;14:920-9. [PMID: 30002711 DOI: 10.5114/aoms.2016.58749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
495 Candia R, Bravo-Soto GA, Monrroy H, Hernandez C, Nguyen GC. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2020;8:CD012328. [PMID: 32746500 DOI: 10.1002/14651858.CD012328.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Lankarani KB, Sivandzadeh GR, Hassanpour S. Oral manifestation in inflammatory bowel disease: A review. World J Gastroenterol 2013; 19(46): 8571-8579 [PMID: 24379574 DOI: 10.3748/wjg.v19.i46.8571] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
497 Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behçet and Crohn's disease: two sides of the same coin. Pediatr Rheumatol Online J 2017;15:33. [PMID: 28427473 DOI: 10.1186/s12969-017-0162-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 8.3] [Reference Citation Analysis]
498 Mikkelsen G, Lillebo B, Faxvaag A. Disease-associated reference intervals for twenty laboratory tests in patients with rheumatoid arthritis, Crohn's disease or ulcerative colitis. Pract Lab Med 2021;25:e00225. [PMID: 34095413 DOI: 10.1016/j.plabm.2021.e00225] [Reference Citation Analysis]
499 von Martels JZH, Bourgonje AR, Klaassen MAY, Alkhalifah HAA, Sadaghian Sadabad M, Vich Vila A, Gacesa R, Gabriëls RY, Steinert RE, Jansen BH, Bulthuis MLC, van Dullemen HM, Visschedijk MC, Festen EAM, Weersma RK, de Vos P, van Goor H, Faber KN, Harmsen HJM, Dijkstra G. Riboflavin Supplementation in Patients with Crohn's Disease [the RISE-UP study]. J Crohns Colitis 2020;14:595-607. [PMID: 31873717 DOI: 10.1093/ecco-jcc/jjz208] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
500 Ciccocioppo R, Cangemi GC, Kruzliak P, Gallia A, Betti E, Badulli C, Martinetti M, Cervio M, Pecci A, Bozzi V, Dionigi P, Visai L, Gurrado A, Alvisi C, Picone C, Monti M, Bernardo ME, Gobbi P, Corazza GR. Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn's disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. Stem Cell Res Ther 2015;6:137. [PMID: 26206376 DOI: 10.1186/s13287-015-0122-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
501 Kameli N, Becker HEF, Welbers T, Jonkers DMAE, Penders J, Savelkoul P, Stassen FR. Metagenomic Profiling of Fecal-Derived Bacterial Membrane Vesicles in Crohn's Disease Patients. Cells 2021;10:2795. [PMID: 34685776 DOI: 10.3390/cells10102795] [Reference Citation Analysis]
502 Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
503 Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front Med (Lausanne). 2014;1:3. [PMID: 25685754 DOI: 10.3389/fmed.2014.00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
504 Degagné E, Saba JD. S1pping fire: Sphingosine-1-phosphate signaling as an emerging target in inflammatory bowel disease and colitis-associated cancer. Clin Exp Gastroenterol 2014;7:205-14. [PMID: 25061328 DOI: 10.2147/CEG.S43453] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.7] [Reference Citation Analysis]
505 Tian T, Wang Z, Zhang J. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. Oxid Med Cell Longev 2017;2017:4535194. [PMID: 28744337 DOI: 10.1155/2017/4535194] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 36.0] [Reference Citation Analysis]
506 Rafia R, Scope A, Harnan S, Stevens JW, Stevenson M, Lobo A. Vedolizumab for Treating Moderately to Severely Active Crohn's Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics 2016;34:1241-53. [PMID: 27480631 DOI: 10.1007/s40273-016-0436-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
507 Tse CS, Deepak P, Smyrk TC, Raffals LE. Isolated Acute Terminal Ileitis Without Preexisting Inflammatory Bowel Disease Rarely Progresses to Crohn's Disease. Dig Dis Sci 2017;62:3557-62. [PMID: 29064015 DOI: 10.1007/s10620-017-4803-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
508 Galazzo G, Tedjo DI, Wintjens DSJ, Savelkoul PHM, Masclee AAM, Bodelier AGL, Pierik MJ, Jonkers DMAE, Penders J. Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease. J Crohns Colitis 2019;13:1273-82. [PMID: 30810207 DOI: 10.1093/ecco-jcc/jjz049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
509 Qian K, Yuan L, Wang S, Kuang Y, Jin Q, Long D, Jiang Y, Zhao H, Liu K, Yao H. Inhibitor of apoptosis-stimulating p53 protein protects against inflammatory bowel disease in mice models by inhibiting the nuclear factor kappa B signaling. Clin Exp Immunol 2021;205:246-56. [PMID: 33942299 DOI: 10.1111/cei.13613] [Reference Citation Analysis]
510 Bähler C, Vavricka SR, Schoepfer AM, Brüngger B, Reich O. Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014. BMC Gastroenterol 2017;17:138. [PMID: 29197335 DOI: 10.1186/s12876-017-0681-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
511 Coskun M. Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne) 2014;1:24. [PMID: 25593900 DOI: 10.3389/fmed.2014.00024] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 7.6] [Reference Citation Analysis]
512 M’Koma AE. Diagnosis of inflammatory bowel disease: Potential role of molecular biometrics. World J Gastrointest Surg 2014; 6(11): 208-219 [PMID: 25429322 DOI: 10.4240/wjgs.v6.i11.208] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
513 Bendix M, Dige A, Deleuran B, Dahlerup JF, Jørgensen SP, Bartels LE, Husted LB, Harsløf T, Langdahl B, Agnholt J. Flow cytometry detection of vitamin D receptor changes during vitamin D treatment in Crohn's disease. Clin Exp Immunol 2015;181:19-28. [PMID: 25707738 DOI: 10.1111/cei.12613] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
514 Rumman A, Candia R, Sam JJ, Croitoru K, Silverberg MS, Steinhart AH, Nguyen GC. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2017;2017:7365937. [PMID: 28239601 DOI: 10.1155/2017/7365937] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
515 Robinson AM, Rahman AA, Miller S, Stavely R, Sakkal S, Nurgali K. The neuroprotective effects of human bone marrow mesenchymal stem cells are dose-dependent in TNBS colitis. Stem Cell Res Ther 2017;8:87. [PMID: 28420434 DOI: 10.1186/s13287-017-0540-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
516 Lee SM, Lee KH, Park SY, Kim DH, Chung JO, Ju JK, Lee JH, Kim HS. Expression of Cyr61 is associated with clinical course in patients with Crohn's disease. BMC Gastroenterol 2021;21:129. [PMID: 33743589 DOI: 10.1186/s12876-021-01713-9] [Reference Citation Analysis]
517 Qiu Y, Li MY, Feng T, Feng R, Mao R, Chen BL, He Y, Zeng ZR, Zhang SH, Chen MH. Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn's disease. Stem Cell Res Ther 2017;8:136. [PMID: 28583202 DOI: 10.1186/s13287-017-0570-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
518 Morís G. Inflammatory bowel disease: An increased risk factor for neurologic complications. World J Gastroenterol 2014; 20(5): 1228-1237 [PMID: 24574797 DOI: 10.3748/wjg.v20.i5.1228] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
519 Belvedere A, Scoglio R, Viola A, Costantino G, Sitibondo A, Muscianisi M, Inferrera S, Alibrandi A, Fries W. A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy. Acta Biomed 2021;92:e2021161. [PMID: 33988169 DOI: 10.23750/abm.v92i2.9593] [Reference Citation Analysis]
520 Krela-Kazmierczak I, Szymczak-Tomczak A, Tomczak M, Lykowska-Szuber L, Eder P, Kucharski MA, Stawczyk-Eder K, Waszak K, Karczewski J, Dobrowolska A. Is there a relation between vitamin D, interleukin-17, and bone mineral density in patients with inflammatory bowel disease? Arch Med Sci 2021;17:662-74. [PMID: 34025836 DOI: 10.5114/aoms.2018.78009] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
521 Bahrami G, Malekshahi H, Miraghaee S, Madani H, Babaei A, Mohammadi B, Hatami R. Protective and Therapeutic Effects of Aloe Vera Gel on Ulcerative Colitis Induced by Acetic Acid in Rats. Clin Nutr Res 2020;9:223-34. [PMID: 32789152 DOI: 10.7762/cnr.2020.9.3.223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Gao C, Liu L, Zhou Y, Bian Z, Wang S, Wang Y. Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease. Chin Med 2019;14:23. [PMID: 31236131 DOI: 10.1186/s13020-019-0245-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
523 Dotti I, Salas A. Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018;24:2501-2509. [PMID: 30169820 DOI: 10.1093/ibd/izy275] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
524 Ananthakrishnan AN, Cagan A, Cai T, Gainer VS, Shaw SY, Savova G, Churchill S, Karlson EW, Murphy SN, Liao KP, Kohane I. Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis 2016;22:151-8. [PMID: 26332313 DOI: 10.1097/MIB.0000000000000580] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
525 Sun L, Kong R, Li H, Wang D. The Role of T Follicular Helper Cells and Interleukin-21 in the Pathogenesis of Inflammatory Bowel Disease. Gastroenterol Res Pract 2021;2021:9621738. [PMID: 34471409 DOI: 10.1155/2021/9621738] [Reference Citation Analysis]
526 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
527 Yu Y, Zhu S, Li P, Min L, Zhang S. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis 2018;9:961. [PMID: 30237392 DOI: 10.1038/s41419-018-0982-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
528 Chaparro M, Aterido A, Guerra I, Iborra M, Cabriada JL, Bujanda L, Taxonera C, García-Sánchez V, Marín-Jiménez I, Barreiro-de Acosta M, Vera I, Martín-Arranz MD, Hernández-Breijo B, Mesonero F, Sempere L, Gomollón F, Hinojosa J, Bermejo F, Beltrán B, Rodríguez-Pescador A, Banales JM, Olivares D, Aguilar-Melero P, Menchén L, Ferreiro-Iglesias R, Blazquez Gómez I, Benitez García B, Guijarro LG, Marin AC, Bernardo D, Marsal S, Julia A, Gisbert JP. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease. Therap Adv Gastroenterol 2019;12:1756284819867848. [PMID: 31598133 DOI: 10.1177/1756284819867848] [Reference Citation Analysis]
529 施嫣红, 翁韵, 刘占举. 血清英夫利昔单抗浓度检测对炎症性肠病患者疗效的评估价值. 世界华人消化杂志 2015; 23(31): 4946-4953 [DOI: 10.11569/wcjd.v23.i31.4946] [Reference Citation Analysis]
530 Rolandsdotter H, Jönsson-Videsäter K, L Fagerberg U, Finkel Y, Eberhardson M. Exclusive Enteral Nutrition: Clinical Effects and Changes in Mucosal Cytokine Profile in Pediatric New Inflammatory Bowel Disease. Nutrients 2019;11:E414. [PMID: 30781421 DOI: 10.3390/nu11020414] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
531 Liu TC, Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol. 2016;11:127-148. [PMID: 26907531 DOI: 10.1146/annurev-pathol-012615-044152] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 25.4] [Reference Citation Analysis]
532 Bouland GA, Beulens JWJ, Nap J, van der Slik AR, Zaldumbide A, 't Hart LM, Slieker RC. CONQUER: an interactive toolbox to understand functional consequences of GWAS hits. NAR Genom Bioinform 2020;2:lqaa085. [PMID: 33575630 DOI: 10.1093/nargab/lqaa085] [Reference Citation Analysis]
533 Han Y, Zhang L, Li W, Liu X, Xiao J, Chen G, Li N. Natural CAC chemopreventive agents from Ilex rotunda Thunb. J Nat Med 2019;73:456-67. [PMID: 30758715 DOI: 10.1007/s11418-019-01281-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
534 McHardy IH, Goudarzi M, Tong M, Ruegger PM, Schwager E, Weger JR, Graeber TG, Sonnenburg JL, Horvath S, Huttenhower C, McGovern DP, Fornace AJ Jr, Borneman J, Braun J. Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships. Microbiome 2013;1:17. [PMID: 24450808 DOI: 10.1186/2049-2618-1-17] [Cited by in Crossref: 155] [Cited by in F6Publishing: 141] [Article Influence: 19.4] [Reference Citation Analysis]
535 Boyapati RK, Rossi AG, Satsangi J, Ho GT. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol. 2016;9:567-582. [PMID: 26931062 DOI: 10.1038/mi.2016.14] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
536 Wang R, Yao Q, Chen W, Gao F, Li P, Wu J, Yu J, Cao H. Stem cell therapy for Crohn's disease: systematic review and meta-analysis of preclinical and clinical studies. Stem Cell Res Ther 2021;12:463. [PMID: 34407875 DOI: 10.1186/s13287-021-02533-0] [Reference Citation Analysis]
537 Antwi-Baffour S, Kyeremeh R, Adjei JK, Aryeh C, Kpentey G. The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights 2016;7:6. [PMID: 26935316 DOI: 10.1007/s13317-016-0078-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]